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Abstract 
 
Orphenadrine citrate is a muscle relaxant that is marketed as tablets and ampoules, topical 
preparations are promising due to the ease of application and acceptability by the patients, but 
they are not effective because they do not penetrate the skin well. 
 The aim of this thesis is to investigate the effects of some penetration enhancers on permeation 
of newly developed orphenadrine citrate gel, as a model of semisolid topical muscle relaxant 
preparation. 
In the first phase the experiment diffusion parameters of (1% w/v) orphenadrine citrate (OC) 
alone in aqueous solution was specified and used as a reference control to measure the effects of 
different penetration enhancers on its permeability. In the second phase, gel formulations with 
1% OC were used as a reference to measure the effects of the best PE on its permeability in gel 
preparation, also the effect of viscosity, and type of gelling agent on drug permeation rate were 
studied. In the third phase a human skin was used to test the permeation of OC from the selected 
gel-penetration enhancer system.  
Modified Franz diffusion cell was used in this in-vitro study. In the first and second phases the 
membrane was composed of octanol soaked filter membrane sandwiched between two layers of 
dialysis membrane. The receiver is filled with phosphate buffer pH 7.4. The donor compartment 
contained 5ml solution of (OC) in aqueous phase and 5 g in gel phase. In the third phase, the 
stratum corneum of fresh and healthy skin sample obtained from a 42-years old female was used 
to separate the receiver and donor compartments. 
Samples of 1 ml volume were taken from the phosphate buffer at the receiver compartment after 
the first hour, and every half an hour later on up to (6) hrs for each experimental sample. OC was 
quantified by using HPLC at  = 220 nm.  
The solubility of orphenadrine citrate was determined in water and in phosphate buffers with 
different pHs. The highest solubility was found in phosphate buffer pH 7.4 with a value of 2.43 
g/100ml.  
XIX 
 
The compatibility of orphenadrine citrate was tested with different excipients (HPMC, CMC Na, 
PG, MP, Tween 80, Cremophore, SLS, Urea, carbapol, Oleic acid, glycerin  ) for three months at 
room temperature and 40 ºC. It was found that OC is compatible with all excipients except with 
carbapol and SLS, while Urea was compatible at room temperature only. Also O.C showed 
stability over a wide range of pH values. 
The penetration enhancers (PE) under investigation were Cremophor RH40, Tween 80, Sodium 
Lauryl Sulphate, Propylene Glycol, -Cyclodextrin, and Urea. They were added in 1% 
concentration to 1% OC in the donor compartment. Diffusion parameters determined were 
cumulative amount, slope and intercept of cumulative amount which is plotted versus time, TL, 
D, P, and K. The (ER) was used as criteria for selecting the best penetration enhancer.  The 
enhancement ratio of the penetration enhancers studied in aqueous phase has been found to 
increase in the order of: PG < Tween80 < Cyclodextrin < Urea < Cremophore RH40. 
Different trials of gel were formulated using HPMC and CMC Na as gelling agent including 1% 
OC and 0.2% to 1.0% of the selected penetration enhancer. The study was conducted using the 
same MFDC and analytical method.  
The HPMC gel containining 1%API and the selected penetration enhancer (Cremophor RH40) 
showed significant higher enhancement ratio than the CMC Na. gel, and as the PE concentration 
increased the ER increased for both types of gelling agents formulas.  
The final gel formula with the optimal concentration of penetration enhancer was then tested for 
permeation through healthy human skin. The API showed good penetration through the skin with 
a permeability coefficient of 0.0009 cm/hr. 
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Part one 
 
Introduction 
 
 
 
 
 
 
 
 
 
 
 
2 
 
Introduction: 
 
Drug delivery through the skin to the systemic circulation provides a convenient and effective 
route of administration of drugs. However the skin and particularly the stratum corneum resist 
the transfer of drug from the surface of skin towards the systemic circulation.  The Stratum 
corneum is a horny layer composed of dead cells with a thickness of about 10 µm. It is a 
multi-layered “brick and mortar” like structure of keratin rich corneocytes(bricks) in an 
intercellular lipid matrix(mortar). It is markedly hygroscopic; it swells to about three times its 
original thickness when immersed in water. It functions as a protective chemical and physical 
barrier and it is only slightly permeable to water, also it retards water loss from underlying 
tissues (Benson, 2005), (Abate, 2005). 
One of the major challenges that faces the scientists today is formulating drugs that penetrate 
the skin rapidly  without inducing significant irreversible alterations to the skin barrier. An 
approach to do that is by using penetration enhancers, chemicals that interact with the skin 
constituents to promote drug penetration (Kreilgaard, 2002), (Williams, Barry, 2004) 
The mechanism of action of these penetration enhancers on the stratum corneum is either to 
disrupt the stratum corneum intercellular lipid matrix or by increasing the partitioning of drug 
into the stratum corneum. In a case where the drug has a high affinity to a solvent and the 
solvent has a high penetrability to the skin then the portioning into and permeation through 
the skin can be increased by a solvent drug mechanism in which the drug and the solvent 
permeate together. (Abate, 2005), (Kamil 2006). 
The intercellular lipid matrix exists as continuous lipid phase; occupying about 20% of the 
stratum corneum and arranged in multiple lamellar liquid crystal structures, with hydrocarbon 
chains aligned, and polar head groups dissolved in aqueous layer. It resembles the major 
pathway for drug penetration through the skin (Walters, 2002), (Bouwstra, J, Honeywell-
Nguyen,). 
That is the hydrophilic substances diffuse through the hydrophilic region, while the 
hydrophobic substance diffuses through the hydrophobic region.  (Benson, 2005) 
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1.1. Human Skin: 
 
The skin is the largest and heaviest organ of the body accounting for more than 10% of the  
body mass, with an average area of 2m2, it consists of four layers (figure1 .1),  the stratum 
corneum(non viable epidermis), the remaining layers of the epidermis(viable epidermis), 
dermis, and subcutaneous tissue. There are also several associated appendages: hair follicles, 
sweat ducts, and nails.(Walters 2002),( (Abate, 2005)) 
The protective homeostatic role of the skin allows the survival of  humans in the environment:  
 
1- It protects the skin from chemicals, bacteria, allergins, fungi and radiations(Walters, 
2002) 
2- It is responsible for heat regulation, and blood pressure control Bouwstra, J, 
Honeywell-Nguyen, P. (2002) 
3- It protects the body against  loss of endogenous material (Bouwstra, Honeywell-
Nguyen,2002) 
4- It forms a barrier to the external environment maintaining body fluids and excluding 
harmful substances(Yamashita, Hashida, 2003) 
5- It is considered a site of administration of drugs for topical and systemic 
therapy(Yamashita, Hashida,2003) 
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Figure 1.1: Skin structure(Bronaugh,, Maibach, 2005) 
 
 
1.2. Stratum corneum 
 
The stratum corneum, the outermost layer of epidermis(figure 1.2) , is the primary barrier 
against permeation of topically applied drugs((Yamashita, Hashida,2003)). It is approximately 
10-20µm thick(Walter, 2002) 
It consists of keratin filled dead cells( the corneocytes) which are entirely surrounded by 
crystalline lamellar lipid region. The cell boundary , the cornified envelope is, a very densely 
cross linked protein structure  which reduces absorption of drugs into the cell. For This reason 
most of the active substances applied onto the skin are diffusing along through the lipid 
lamellae in the intercellular region (Bouwstra, Honeywell-Nguyen, 2002). Its now well 
recognized that most solutes enter the body through the less than 0.1µm –wide  intercellular 
region of the stratum corneum(Walter,  2002): The cells of stratum corneum originate in the 
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viable epidermis and undergo many morphological changes before desquamation. (Walter, 
2002) 
The basal layer is composed of (1-2) cell layers, the stratum spinosum (2-7) cell layers, and 
the stratum granulosum 2-3 cell layers, while the stratum corneum have more than 25 cell 
layers (Forslind, Lindberg, 2004) 
In the basal layer cells proliferate, upon leaving the basal layer cells starts to differentiate and 
migrate in the direction of the skin surface. At the interface between stratum granulosum and 
stratum corneum (figure 1.3) final differentiation occurs, during which the viable cell is 
transformed into dead keratin filled cells (corneocytes).  
Epidermal differentiation is a major events that includes extrusion of lamellar bodies, loss of 
nucleus, and increasing amount of keratin in the stratum corneum  (Riviere, 2006). 
 
Figure 1.2: Stratum corneum (Walter,  2002) 
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The Top layer of the skin , The stratum corneum is important for the appearance and function 
of the skin, it serves as a protective physical and chemical barrier and it is only slightly 
permeable to water(Abate, et al , 2005). It has an average turnover of approximately three 
weeks. (Walter, 2002) 
Hydration of the stratum corneum can lead to profound changes in its barrier properties, it 
induces swelling of the corneocytes and the expansion of intercellular lipid lamella. Stratum 
corneum water content can be increased from 15-20% up to 400% of dry weight. The 
structure of the stratum corneum has been likened to ‘‘bricks-and-mortar’’, where the bricks 
are the component cells, or corneocytes, and the mortar is the intercellular lipids (Walter, 
2002) 
 
 
 
 
 
Figure 1.3: Morphological changes of stratum corneum cells (Benson, 2005) 
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1.3. Dermis 
 
The  dermis is a connective tissue (Ranade, Hollinger, 2004) which is a critical component of 
the body that provides nutritive, immune and support for the epidermis, and play a role in 
temperature pressure and pain regulation. It is about 0.1-0.5 cm  thick consisting of about 
70% of collagenous fibers providing Cushioning and elasticity. The blood flow rate to the 
skin is about 0.05 ml min-1 cc-3  (Walter, 2002) 
The dermis apparently is a gel structure, a fibrous protein(collage, elastin) matrix embded in 
an amorphous colloidal ground substance. Blood vessels , lymphatics are within dermis. 
(Abate, et al 2005) 
 
1.4. Subctaneous 
 
The sub cutaneous fat layer serves as a cushion for the dermis and epidermis, and it is 
important for insulation. Figure 1.4.  summarizes the function of the skin( Walter, K. 2002) 
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Figure 1.4: Summary of Skin structure and Function( Walter, K. 2002) 
1.5.  Intercellular lipids 
The intercellular region consists mainly of lipids and desmosomes for corneocyte cohesion( 
Walter, K. 2002). The composition of the stratum corneum lipids strongly differs from that of 
cell membranes of living cells. Major lipids are Ceramides(CER), Cholestrol(CHOL), and 
free fatty acids (See figure 1.5). The length of acyl chain of CER varies between 16-33 
carbons.While fatty acids chain are mostly C22 and C24 (Bouwstra,  Honeywell-Nguyen, 
2002). 
The intercellular lipids occupy 20% of the Stratum corneum. It is composed of 
Cholesterol(27%), ceramides(41%), free fatty acids(9%), cholesteryl esters (10%) and 
cholesteryl sulfate 2%. Ceramide 1-8 with 1 is the least polar (Stabilizer of the intercellular 
lipids). ( Walter, K. 2002). 
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Creation of free space (free volume) in the intercellular lipid lamellae of the stratum corneum 
allows a greater mobility of the hydrocarbon chains that may result in enhanced diffusivity. 
This could be induced by enhancer shape for example, oleic acid and laurocapram (Azone)] or 
by electrostatic head group interactions. ( Walter, K. 2002). 
The combination of the long chain soaps and carboxylic acids spontaneously form a layered 
structure when combined with water in certain portions .Water soluble compounds dissolve in 
the aqueous layer while lipid compounds dissolve in the hydrocarbon region of the 
structure(Friberg, et al, 1987). 
The intercellular lipids matrix is  generated by keratinocytes in the mid to the upper part of the 
stratum granulosun discharging their lamellar content into the intercellular space . (Benson,   
2005) In the initial layers of the stratum corneum this extruded material rearranges to form 
broad intercellular lipid lamella which then associates into lipid bilayers , with the 
hydrocarbon chains aligned and polar head groups dissolved in aqueous layer.(figure 1.5).  
The hydrocarbon chains are arranged in region of crystalline , lamellar gel and lamellar liquid 
crystal phases by creating  various domains within the lipid bilayers Water acts as a plasticizer 
to prevent cracking of the stratum corneum.((Benson,   2005) 
 
 
Figure 1.5: Intercellular lipids. (Moser, et al , 2001) 
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1.6. Transdermal Permeation 
 
Transdermal permeation, or percutaneous absorption, can be defined as the passage of a 
substance, such as a drug, from the outside of the skin through its various layers into the 
bloodstream,  preferably at a specific rate (Ranade, Hollinger, 2004), (Walker, Smith, 1996). 
The exposure of the skin to a dosage form creates a concentration difference which the active 
ingridient must partition, followed by diffusion of the compound through the external strata to 
the dermis.( Walker, Smith, 1996), (Cevec, et al, 1996) 
The barrier properties of the Stratum corneum are now recognized the major rate-limiting step 
in the diffusion process of a drug permeating across skin (Walter, 2002). 
Despite the small number of drugs delivered through the transdermal route , it is estimated 
that the wordwide market revenues of this route are about three billion dollars (Benson, 2005) 
Transport across the stratum corneum  is largely a passive process, and thus the 
physicochemical properties of a permeant are an important determinant of its ability to 
penetrate and diffuse across the membrane. Once it has penetrated through the epidermis, a 
compound may be carried away by the dermal blood supply or be transported to deeper 
tissues ( Walter, 2002).  
Transderml permeation can be attained by the combination of appropriate solute, properties 
for skin with appropriate dosage form design (e.g., patches, gels, creams, ointments). ( Walter, 
2002) 
 
Advantages of transdermal absorption:  
1- Avoid the problem of stomach emptying, pH effects, enzymes(drug deactivation). 
 ( Walter, 2002) 
2- Avoid hepatic first pass effect ( Walter, 2002) 
3- Ability to discontinue administration by removal of the system (Kanikkannan,  et al , 
1999) 
 
Difficulties of transdermal permeation ( Walter, 2002): 
1- Variability of transdermal absorption regarding to site of application  
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2- Skin metabolic effect 
3- Irritation and toxicity to the skin 
 
Disadvantages of transdermal delivery (Walter, 2002): 
 The main drawback being that not all compounds are suitable candidates for 
transdermal absorption 
 diffusion rate can differ between individuals(races, ages, skin conditions and diseases) 
 Diminished skin absorption may start to be observed with compounds of molecular 
weight above 500 Da.(Bronaugh,  Maibach, 2005) 
 
There are generally considered to be three routes by which compounds can diffuse across the 
SC (Walter, 2002): 
   
1- Transcellular,  
2- Intercellular 
3-  Transappendageal  
 
1.6.1. Transcellular route 
 
It was originally believed in the past that transcellular diffusion mechanisms dominated over 
the intercellular and transappendageal routes during the passage of solutes through the stratum 
corneum. However, the transport by the transcellular route would involve the repeated 
partitioning of the molecule between lipophilic and hydrophilic compartments, including the 
almost impenetrable corneocyte intracellular matrix of keratin.  Most experimental evidence 
now suggests that transport through the stratum corneum is by the intercellular route (Walter, 
2002) 
 
1.6.2. Intercellular route 
 
The intercellular stratum corneum spaces were initially dismissed as a potentially significant 
diffusion pathway because of the small volume they occupy. However, the physical structure 
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of the intercellular lipids was thought to be a significant factor in the barrier properties of the 
skin. Tracer studies provided evidence that the intercellular lipids are the main epidermal 
permeability barrier 
Two key determinants for a solute crossing a membrane are solubility and diffusivity. The 
relative solubility of a solute in two phases determines its partition coefficient and therefore, 
the likelihood of the solute being taken up into the Stratum corneum from a vehicle. Also, 
solubility will determine whether a solute is likely to be desorbed from the Stratum corneum 
into deeper layers. The diffusivity is a measure of the speed at which a solute crosses. 
In the first step of the transport process, molecules must be in solution in the vehicle to 
partition from the vehicle into the lipids in the outermost part of the SC; they must then 
diffuse through it; partition back out of the Stratum corneum and into the viable epidermis. 
Next, molecules diffuse through the viable epidermis and papillary dermis. 
At the capillary plexus a high percentage of molecules are transferred into the circulating 
blood and a lower percentage diffuses into deeper tissues. (Walter, 2002) 
The physicochemical properties of the diffusing drug and the vehicle (e.g., molecular size, 
stability, binding affinity, solubility, and partition coefficient),( Ranade, Hollinger, 2004), 
(Benson, 2005) influence permeation across the stratum corneum and thereby optimize the 
delivery.  
The maximum skin penetration rate is obtained when a drug is in a supersaturated solution 
((Benson, 2005). Also hydration of the skin cause swelling of the stratum corneum and 
decreases protein network density and diffusional pathway length.(can be done by occlusion) 
(Abate, 2005). 
 
1.6.3 Appendageal route. 
Apandageal route is limited to about  0.1% of total surface area of the skin (Barry, 2002) and 
include sweat ducts and hair follicles (Walter, 2002). Penetration through hair follicles is 
responsible for the presteady state permeation of polar molecules and the flux of large polar 
molecules and ions  that have difficulty diffusing through the stratum corneum.  
Majority of penetration enhancement techniques focus on increasing the transport of drugs 
through the stratum corneum due to it large surface area(Benson,2005) 
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1.7. Penetration enhancers 
 
There are physical and chemical transdermal enhancement techniques. Physical penetration 
ennhancement involves an externally applied force to augment the delivery of the target agent 
across the skin. Examples are iontophoresis (the use of a small electric current), sonophoresis 
(the use of ultrasound), and electropermeabilization (the use of short-duration, high-voltage 
electric pulses). (Potts, Guy, 1997) 
Another approach for improving transdermal drug delivery uses chemical penetration 
enhancers (also called sorption promoters or accelerants) which penetrate into skin to 
reversibly decrease the barrier resistance.( Williams, Barry, 2004).  Penetration enhancers 
may disrupt the packing of the intercellular lipid matrix or may increase the drug partitioning 
into the tissue by acting as a solvent for the permeant within the membrane ( Williams, Barry, 
2004). See figure (1.6). 
 
Desirable properties of penetration enhancers are ( Williams, Barry, 2004).    
 
1- They should be non-toxic, non-irritating and nonallergenic.  
2- They would ideally work rapidly, and the activity and duration of effect should be 
both predictable and reproducible.  
3- They should have no pharmacological activity within the body—i.e. should not bind to 
receptor sites.  
4- The penetration enhancers should work unidirectionally, i.e. should allow therapeutic 
agents into the body whilst preventing the loss of endogenous material from the body.  
5- When removed from the skin, barrier properties should return both rapidly and fully. 
6- . The penetration enhancers should be appropriate for formulation into diverse topical 
preparations, thus should be compatible with both excipients and drugs.  
7- . They should be cosmetically acceptable with an appropriate skin ‘feel’. 
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Figure 1.6: Disruption of intercellular lipids by penetration enhancers(Williams, Barry, 2004).   
 
Many Penetration enhancers such as Azone, DMSO, Alcohols,, fatty acids and terpenes  have 
been shown to  increase permeability by disordering (fluidizing) the lipid structure of the 
sratum corneum. 
Other penetration enhancers such as oleic acid , at high concentration, pool within the lipid 
domains to create permeable pores. In addition to their effect on stratum corneum lipids, urea 
and surfactants also react with keratin and may result in a disruption of order within the 
corneocyte (Smith,  Maibach, 2006) 
Urea promotes transdermal permeation by facilitating hydration of the stratum corneum and 
by the formation of hydrophilic diffusion channels within the barrier (Walker, Smith,1996). 
A number of solvents increase permeant partitioning  and solubility within the stratum 
corneum(Propylene glycol, ethanol)  (Smith,  Maibach, 2006). 
Soaking the skin in water, exposing the membrane to high humidities or, as is more usual 
under clinical conditions, occluding the tissue so preventing transepidermal water loss can 
allow the stratum corneum to reach water contents in equilibrium with that of the underlying 
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epidermal skin cells. Thus, on occlusion, the water content of this outer membrane can 
approach 400% of the tissue dry weight. (( Williams, Barry, 2004).  ) 
Freeze Fracture electron microscopy showed that fully hydrated stratum corneum shows that 
the intercellular lipid bilayers contain water pools with occasional vesicle-like structures 
(Touitou, Barry, 2007) 
It is difficult to select rationally a penetration enhancer for a given permeant. Penetration 
enhancer potencies appear to be drug specific, or at best may be predictive for a series of 
permeants with similar physico-chemical properties (such as similar partition coefficients, 
molecular weights and solubilities). Some broad generic trends are apparent, such as the use 
of hydrocarbon monoterpenes for lipophilic permeants, but the level of enhancement expected 
for these agents is unpredictable. (( Williams, Barry, 2004).   
 
1.8. Orphenadrine citrate 
 
Orphenadrine citrate is the citrate salt of orphenadrine (2-dimethylaminoethyl 2-
methylbenzhydryl ether citrate)(figure 1.7). It is a congener of diphenhydramine and a tertiary 
amine (Sweetman, 2007) 
 
Figure 1.7: Chemical structure of Orphenadrine citrate 
 
 It occurs as a white, crystalline powder having a bitter taste. It is practically odorless; 
sparingly soluble in water, slightly soluble in alcohol. It melts at 136 °C (The Stationary 
office, 2005),Molecular weight of orphenadrine citrate is 461.5. The mode of therapeutic 
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action has not been clearly identified, but may be related to its analgesic properties. 
Orphenadrine citrate also possesses anti-cholinergic actions. ( Abate,  et al 2005) 
It relieves the discomfort asscociated with acute painful  muscoskeletal conditions by a mode 
of action not quite defined. It also has weak antihistaminic and local anaesthetic properties.  
It is given by mouth in a dose of 100 mg twice daily or by intramuscular or slow intravenous 
injection in a dose of 60 mg which could be repeated every 12 hours (Thomson PDR, 2006) 
Orphenadrine citrate has been used in some countries for the treatment of intractable hiccup 
(Sweetman, 2007) 
The half-life of orphenadrine has been reported to be 14 hours (Sweetman, 2007) 
Orphenadrine citrate should be used cautiously in patients with gastrointestinal obstruction. 
Orphenadrine citrate is used as hydrochloride and citrate salts (Sweetman, 2007) 
In one study orphenadrine citrate showed an anticholinergic effect directly on muscurinic 
receptors in chicken heart, rabbit lung, rabbit heart ( Lazareno,  et al, 1990).  Orphenadrine 
citrate is a non competitive antagonist at NMDA receptor complexes. In addition the drug is 
an antagonist at histamine receptors H1 also it may act as antagonist at M1, M2,M3, M4 
muscarinic acetylcholine receptors (Neurotransmitters.net, 2008) 
 
1.9. Gels 
 
Gels are semi solid systems in which a liquid phase is trapped within an interlocking three 
dimensional polymeric matrix of a natural or synthetic gum. A high degree of physical or 
chemical cross linking of the polymer is involved. Gelling agents include Carboxymethyl 
cellulose(Banker, Rhodes, 2002), HPMC gelling agent (Mohamed, 2004).  Gels have 
favorable properties such as being greaseless, easily spreadable, easily removable, emollient, 
non staining, compatible with several excipients and water soluble or miscible,  thixotropic 
(Mohamed, 2004). The preparation of gels can involve high temperature processing. It is 
easier to disperse methyl cellulose in hot than in cold water. The polymer then goes into 
solution and thickens or sets up as the temperature is lowered. (Banker, Rhodes, 2002). Gels 
can be investigated visually such as color , homogeneity, consistency, spreadability, and 
phase separation. (Mohamed, 2004). 
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In vitro dissolution method for topical dosage forms is based on an open champer diffusion 
cell system such as Franz cell, fitted usually with a synthetic membrane. The test product is 
placed in the donor compartment of the diffusion cell and a sampling fluid is placed on the 
other side of the membrane in a receptor compartment. Diffusion of the product through the 
membrane is monitored by assay. (According to FDA) This guideline is the most commonly 
used method (Abate, et al, 2005). 
 
1.10. In vitro diffusion cells and skin isolation 
 
Most common methods for evaluation of in vitro skin penetration is using diffusion cells, The 
major advantage of in vitro investigations is that the experimental conditions can be 
controlled precisely, such that the only variables are the skin and the test material. 
Diffusion equations that are applied to the in vitro situation make the following 
assumptions(Walter,  2002): 
 
1. The receptor phase is a perfect sink.  
2. Depletion of the donor phase is negligible. 
3. The membrane is a homogeneous slab.  
 
A well-designed skin diffusion cell should (Walter,  2002) 
1. Be inert 
2. Be robust and easy to handle 
3. Allow the use of membranes of different thicknesses 
4. Provide thorough mixing of the receptor chamber contents 
5. Ensure intimate contact between membrane and receptor phase 
6. Be maintainable at constant temperature 
7. Have precisely calibrated volumes and diffusional areas 
8. Maintain membrane integrity 
9. Provide easy sampling and replenishment of receptor phase 
10. be available at reasonable cost 
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Franz diffusion cell(figure1.8) is composed of (Kamil, 2006):  
 
1- Donor compartment 
2- Receiver compartment 
3- Two sampling ports 
4- Water jacket 
 
 
To isolate the Stratum corneum from epidermal membranes, the latter is placed in trypsin 
solution (0.0001%), incubated at 37Cº for 12 h, rubbed (with a cotton bud) to remove the 
epidermal cells, rinsed in distilled water, and air-dried on a surface from which they can be 
easily removed. 
In vitro skin diffusion experiments are normally conducted with a skin temperature of 32Cº 
(the in vivo value of the human skin) (Walter,  2002) 
 
As human skin is difficult to obtain. Several membrane were  used to simulate skin, including 
cellulose acetate, silicon,  egg shell membrane but all these membranes are not as complex as 
human skin. (Aulton, 1996). 
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Figure 1.8: Modified Franz diffusion cell 
 
1.11. Diffusion Theory 
 
Simple diffusion laws can be used to describe the percutaneous absorption process  (Guy, 
Hadgraft, 2003) 
Diffusion is defined as a process of mass transfer of individual molecules of a substance, 
brought about by random molecular motion and associated with concentration gradient; the 
flow of a molecule through a membrane is a convenient way to study diffusion (Martin, et al, 
1983). 
Fick’s first law : 
The amount M of material flowing through a unit cross section S, of a barrier in unit time, t, is 
known as the flux, J: 
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J= 


    ..................................................... (1) 
 
The flux in turn is proportional to concentration gradient, dC/dx: 
J= -D 


  ……………………………….… (2) 
 
In which D is the diffusion coefficient of a penetrant in cm2 /sec, C its concentration g/cm3 
and x is the distance in cm of movement perpendicular to the surface of the barrier, t usually 
in seconds and S in cm2 , the negative sign indicates that the diffusion is in the direction of 
decreasing concentration. 
An equation for mass transport that emphasizes the change in concentration with time at a 
definite location rather than the mass diffusing across a unit area of a barrier in unit time is 
known as Fick’s second law 
The concentration of diffusant in volume element changes with time, C/t as the flux or 
amount diffusing changes with distance J/x: 
 


 = - 
	

  ………………………………….. (3) 
 
Differentiating the first law expression, equation (2) with respect to x one obtains : 
 
- 
	

 = D
²
²
  ……………………………… (4) 
 
Substituting c/t from  equation (3) into equation (4) results in Fick’s second law: 
 



= D 
²
²
  ……………………………….. (5) 
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Fick’s second law states that the change in concentration with time in a particular region is 
proportional to the change in concentration gradient at that point in the system. 
An important condition in diffusion is the steady state. Fick’s first law, equation (2), gives the 
flux or rate of diffusion through unit area in the steady state of flow while the second law 
refers in general to a change in concentration of diffusant with time at any distance (equation 
(5)). 
Originally the diffusate concentration will fall in the donor compartment and will increase in 
the receiver one until the system come to equilibrium. 
If a membrane separates  the two compartments of a diffusion cell of a cross sectional area S 
and thickness h, and if the concentrations in the membrane on the donor C1 and on the 
receiver C2 respectively (Figure 1.9,  Fick’s first law could be written : 
 
J = 


 =D  


 ……………………... (6) 
 
The concentrations C1 and C2 within the membrane ordinarily are not known but can be 
replaced by the partition coefficient multiplied by the concentration Cd on the donor side of 
the membrane or Cr on the receiver side as follows: 
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Figure 1.9: Donor and receptor compartments separated by a barrier. 
 
K=  


 = 


 ………………………………… (7) 
 
Hence according to equation(6)  
 


 = 




 ...................................... (8) 
 
And if sink conditions is maintained in the receptor then Cr  0 then equation (8) becomes : 
 
  


 = 



 = PSCd  ............................................... (9) 
 
In which 
 
P = 


 cm/sec …………………………………………. (10) 
 
 Where P is the permeability coefficient. 
To calculate diffusion parameters for a specific drug we use a diffusion cell and we put the 
drug solution in the donor phase separated by a membrane from the receptor phase ensuring 
that sink conditions is available, we take samples from the receiver phase at time intervals and 
we plot the curve(see figure 1.10). 
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Figure 1.10: Cumulative amount of drug permeated through a barrier over a time period. 
 
The slope of the steady state plot is dM/dt, the X intercept of the steady state line is TL. 
Going back to equation(9) 
 


 = 



 = PSCd  ............................................... (9) 
 
One concludes that the slope of the plot = PSCd  
The lag time is given by the equation: 
 
TL = 


  ……………………………………………… (12) 
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Experimental 
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2.1. Introduction:  
 
Orphenadrine citrate is an anti-cholinergic drug, It relieves the discomfort asscociated with 
acute painful  muscoskeletal conditions by a mode of action not quite defined. It also has 
weak antihistaminic and local anaesthetic , and analgesic properties.( Sweetman, 2007). 
It is given by mouth in a dose of 100 mg twice daily or by intramuscular or slow intravenous 
injection in a dose of 60 mg which could be repeated every 12 hours(PDR). Orphenadrine 
citrate has been used in some countries for the treatment of intractable hiccup (Sweetman, 
2007). 
In this research a new dosage form of orphenadrine citrate is formulated (gel), and mixed with 
several penetration enhancers in order to increase its permeation through the skin. 
The addition of penetration enhancers may change the physicochemical properties such as 
solubility and partition coefficient which may alter its delivery. 
Gel dosage forms are more acceptable by the patients and can be investigated visually such as 
color, homogeneity, consistency, spreadability, and phase separation. (Mohamed, 2004). 
 
2.2. The aim of this work 
 
In this research a new topical gel formula of orphenadrine citrate is prepared and investigated 
for the effect of several chemical penetration enhancers on the drug permeation rate through a 
synthetic membrane and through human skin using a MFDC. 
 
2.2.1. The specific objectives of this work 
 
1- Determining the solubility of orphenadrine citrate in water and in different pH buffer 
solutions in order to determine the concentration of orphenadrine citrate to be used in 
the formula and the effect of the pH on its solubility. 
2- Studying the compatibility of orphenadrine citrate with the excipients and the 
penetration enhancers in order to determine the materials that can be used for further 
formulation and study. 
3- Selecting the best penetration enhancer in solution depending on diffusion study using 
MFDC and a synthetic membrane. 
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4- Preparation of several gel formulas using different gelling agents,  compatible 
excipients and the best penetration enhancer, while keeping the concentration of the 
orphenadrine citrate constant through all. 
5- Studying the permeability of the best gel formula through a synthetic membrane using 
a MFDC 
6- Determining the effect of gel viscosity on its permeation through a synthetic 
membrane using a MFDC. 
7- Studying the effect of the concentration of the penetration enhancer on the drug 
permeation through a synthetic membrane using MFDC. 
8- Studying the permeation of the best orphenadrine citrate gel formula that penetrated 
the synthetic membrane through human skin using MFDC. 
 
2.3. Materials and Reagents 
 
In this research a synthetic membrane was used in the permeation study. It is obtained by 
sandwiching octanol soaked membrane filter between two layers of water soaked dialysis 
membranes. 
The materials and reagents used in this research are listed in table (2.1). 
 
 
 
 
 
 
 
 
 
27 
 
Table  2.1: Materials and reagents used in the study 
 
Items Source Grade 
Orphenadine citrate Nortec Quimica USP 
Potassium dihydrogen phosphate Merck AR 
Picric acid Merck AR 
Double distilled water Jerusalem Pharmaceuticals BP 
Hydrochloric Acid Merck AR 
Toluene Merck AR 
Carpabol Lubrizol BP 
Triethanolamine Garlot Chemical Terminals BP 
Methyl paraben Sharon Laboratories USP 
Hydroxypropyl methylcellulose FMC USP 
Urea Zhejiang Zhongbuo BP 
Propylene Glycol Dow Chemical company BP 
Oleic Acid Woodland Food Industries USP 
Tween 80 KOLB USP 
Sodium laurylsulphate Merck USP 
Cremophore RH 40 Carmel USP 
Sodium carboxy methyl cellulose CPK Elcco USP 
1-Octanol Sigma-Aldrich AR 
Glycerin Oleo chemicals BP 
Methanol J.T Baker AR 
Acetonitril Mallinckrodt Chemicals AR 
Ammonium phosphate Merck AR 
Trypsin Merck AR 
Sodium Hydroxide Merck AR 
Ammonia solution Merck AR 
Cylodextrin Zhejiang BP 
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2.4. Tools and equipments 
 
Syringes, vials, pipettes, glassware, stands and tubes was supplied by Jerusalem 
pharmaceuticals Tools  and equipments used in the study are listed in table (2.2). 
 
Table 2.2: Equipments and tools used in the study. 
 
Equipment Source/Model 
HPLC Merck- Hitachi. 
U.V. Spectrophotometer Hitachi U2900 
Modifed Franz diffusion cell Jordan University of science and technology work 
shop 
pH meter Metrohm 
Percision Balance Percisia 
Magnetic Stirrer Fried Electronic 
Incubator 25C° Advantec CL-310 
Incubator 40C° Advantec CL-310 
Incubator 37C° WTB binder 
Water Pump Atman At-101 
Synthetic membrane filter HVLP 04700 0.45µm Millipore 
Dialysis membrane Cellu Sep H1 Membrane Filtration Products, Inc. 
Water bath Tuttnauer Co. LTD 
Vaccum filter Sartorious 
Sonicator Elmasonic 
Refrigerator L.G. 
Vaccum pump Millipore 
HPLC Dionex Ult.mate 3000 
Brookfield Digital Viscometer Brookfield engineering laboratories, Inc. 
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2.5. Methods: 
 
2.5.1. Solubility determination 
 
To determine the solubility of Orphenadine citrate in water and in different pH conditions, 
Orphenadrine citrate was added in excess to separate vials containing: 
1- Water 
2- Potassium dihydrogen phosphate Buffer with pH=5  
3- Potassium dihydrogen phosphate Buffer with pH=6 
4- Potassium dihydrogen phosphate Buffer with pH=7.4  
Each vial was shaked, sonicated for 10 minutes and filtered from excess orphenadrine through 
0.45µm filter membrane, The clear solution containing soluble orphenadrine citrate was then 
analyzed spectrophotometricaly  to determine the amount of soluble orphenadrine citrate 
(United States Pharmacopeial Convention, 1990) 
 
2.5.2. Spectrophotometrical analysis of Orphenadrine citrate 
 
200 mg of Trinitrophenol was dissolved in 1000ml toluene, a standard solution of 
orphenadrine citrate  in 0.1M HCL was prepared with concentration of 0.00061g/ml. 2ml of 
each sample was taken and diluted with 25ml 0.1M HCL.  1 ml of each standard, assay 
preparation and 0.1 M HCL (to provide blank) was transfered into separate test tubes, to each 
tube 10ml of toluene and 1ml of 0.1M NaOH were added and shaken for 10 minutes. 
 5ml of each clear toluene layer  was transferred to 3 three separate test tubes containing 5ml 
of Trinitrophenol reagent and mixed; the absorbance of solution at wave length 410nm was 
then recorded. 
The concentration of sample is calculated according to the following equation: 
 
Sample concentration in mg/ml =  
 !" #$% &'(
)*+,-&./,0
#.$01$-1
)*+,-&./,0
)  
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2.5.3. Compatibility and stability studies 
 
In order to investigate the compatibility of orphenadrine citrate with the expected excipients 
and penetration enhancers under study, and to determine the stability of orphenadrine citrate 
in different pH medias the following solutions were prepared: 
 
1- Orphenadrine citrate 1% in water 
2- Orphenadrine citrate 1% and carpabol 2% and triethanolamine 2% 
3- Orphenadrine citrate 1% in phosphate buffer of pH= 7.4 
4- Orphenadrine citrate 1% in phosphate buffer of pH= 6 
5- Orphenadrine citrate 1% in phosphate buffer of pH= 5 
6- Orphenadrine citrate 1% in phosphate buffer of pH= 5.5 
7- Orphenadrine citrate 1% in water and methyl paraben 0.1%  
8- Orphenadrine citrate 1% in water and HPMC 2%  
9- Orphenadrine citrate 1% in water and Urea 10% 
10- Orphenadrine citrate 1% in water and propylene glycol 10% 
11- Orphenadrine citrate 1% in water and oleic acid 0.2 % and tween 80 0.5% 
12- Orphenadrine citrate 1% in water and tween 80 2% 
13- Orphenadrine citrate 1% in water and sodium laurylsulphate 1% 
14- Orphenadrine citrate 1% in water and cremophore RH 40 1% 
15- Orphenadrine citrate 1% in water and cyclodextrin 2% 
16- Orphenadrine citrate 1% in water and Na CMC 2% and glycerin 6% 
Each solution was prepared by adding 1 g of orphenadrine citrate to 80 ml water or buffer and 
sonicated for 10 minutes to dissolve the orphenadrine citrate. The excipients are then added in 
the desired concentration and mixed for 10 minutes, then the volume of solution is completed 
to 100ml. 
Each solution is poured into separate vials, labeled and closed tightly. Vials from each 
solution are placed in an incubator at 40 Cº (Accelerated stability study) and at 25 Cº for three 
months. During this period samples are withdrawn from each solution by a syringe every 
month and analyzed by HPLC according to USP30. (United States Pharmacopeial 
Convention, 2006) 
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2.5.4. Analysis of Orphenadrine citrate by HPLC. 
 
Buffer Preperation: 
0.05 M Ammonium phosphate buffer was prepared by dissolving 5.8g of monobasic 
ammonium phosphate in 1000ml water and the pH adjusted to 7.9 using ammonium 
hydroxide or phosphoric acid 
Mobile Phase Preperation: 
Mobile phase was prepared by mixing the methanol, Ammonium phosphate buffer, and 
acetonitrile in the ratios (9:8:3) respectively. 
Standard Preperation: 
A standard was prepared by adding 90mg orphenadrine citrate to 80ml water and sonicating 
for 10 minutes to dissolve the Orphenadrine citrate, the volume is made up with water to 
100ml to  obtain a concentration of 0.9mg/ml. 
System Sensitivity Solution Preparation: 
A system sensitivity solution is prepared by adding 1ml of the standard solution  to 1000ml 
beaker and completing the volume with water, then 500ml of the diluted solution is added to 
1000ml beaker and the volume is made up with water to 1000ml to obtain a concentration of 
0.00045mg/ml 
Chromatographic Conditions 
The liquid chromatography is equipped with a 220nm detector and a 4.6mm x 15cm colomn 
that contains 5µm packing L1, the flow rate is about 1.5ml/min and the temperature of the 
column is maintained at 40C° 
 
Assay preparation for Compatability and Stability Study: 
The sample is prepared by taking a 2 ml of filtered sample (1% orphenadrine citrate) and 
diluting it to 25ml with bi-distilled water to obtain a theoretical concentration of 0.8mg/ml. 
Procedure: 
Separately inject equal volumes of both Standard and Assay preparation into the HPLC 
maintaining the specified chromatographic conditions and record the readings. 
Calculations: 
The concentration of orphenadrin citrate in sample is calculated as follows 
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2
345
346
 
Where Csa is the concentration of sample and rsa, rst are the HPLC readings of sample and 
standard respectively. 
The percentage of Orphenadrine citrate is calculated by dividing the concentration of sample 
on 0.8 and multiplying by 100 
 
2.6. Diffusion Study 
 
To study the diffusion of Orphenadrine citrate a MFDC was used that have two compartments 
a donor and a receiver one. The sample to be studied for diffusion is placed in the donor phase 
and separated from the receiver phase by a synthetic membrane that resembles the skin barrier 
by its hydrophilic and lipophilic regions. The synthetic membrane was used in the study to 
select the best gel formula with the best penetration, after that the synthetic membrane was 
replaced by fresh Human skin obtained from Ramallah Hospital. 
The receiver phase is formulated to dissolve the diffused drug through the membrane or the 
skin. 
 
2.6.1. Preparation of synthetic membrane 
 
The Synthetic membrane is composed from three layers, a HVLP Filter membrane layer with 
pore size 0.45µm, the filter membrane is soaked in octanol for 24 hours to resemble the 
lipophilic layer of intercellular lipids in the stratum corneum. 
Two dialysis membranes are soaked in water for half an hour before the diffusion experiment 
begins. The HVLP filter membrane is sandwiched between the two dialysis membranes to 
prevent the octanol from leaving the filter membrane and to resemble the aqueous layer of the 
skin (Mohammad, 2004). The dialysis membrane used had a molecular weight cutoff of 
10000. 
 
2.6.2. Preparation of Human Skin 
 
A fresh and healthy skin sample was obtained from Ramallah Hospital, it was obtained from a 
female patient in the 40s who had breast surgery. The stratum corneum, the main barrier 
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against permeation of drugs into the human body, was used to separate the receiver and donor 
compartments of the MFDC..The adipose tissue from the skin sample is removed as much as 
possible and the skin is immersed in trypsin solution for 12 hours at 37Cº (Walter, 2002). 
After that the stratum corneum is removed carefully from the rest of the skin by a tweezers, 
rubbed with a cotton bud to remove any depresses, washed with distilled water and dried 
(Walter, 2002) 
 The dried Stratum corneum is then mounted on a Franz diffusion cell and diffusion study is 
performed. 
 
2.6.3. The Receiver Phase. 
 
A phosphate buffer with pH 7.4 was used in the receiver compartment to dissolve the 
orphenadrine citrate that penetrated through synthetic membrane or through the human skin. 
The pH of the receiver compartment is the same as the pH of Human blood (7.4). The 
phosphate buffer was prepared by dissolving 6.8g of KH2PO4 in 1000ml of bi-distilled water.  
The pH is then adjusted by a solution of 5M NaOH to the desired pH. 
The receptor phase was then degassed by heating the buffer to 45Cº and vacuum filtration 
through a HVLP filter membrane with pore size of 0.45µm.  
Degassing is very important, in order to keep the receiver phase bubble free when stirring to 
maintain sink conditions. If not degassed bubbles will appear due to stirring and will stick 
under the separating membrane in the MFDC. This will lead to a decrease in the permeable 
area of the separating membrane resulting in decreased permeability and faulty results. 
   
2.6.4. Diffusion Procedure 
 
An in and out rubber tubes are attached to the inlet and outlet of the water jacket of the MFDC 
and the receiver compartment of the MFDC is fixed in place using a stand and a clamp. 
A water pumb is introduced in the water bath to pump the water from the water bath through 
the water jacket of the MFDC and back to the water bath to maintain a stable temperature of 
32±2 Cº. The water bath is switched on and its temperature is set to 34±2 Cº to maintain a 
temperature of 32 Cº±2 in the MFDC . At this point the water pump is still off. 
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The receiver compartment is filled to top with the phosphate buffer of pH=7 and a magnetic 
bar is introduced in the compartment. The octanol soaked membrane is sandwiched between 
two water soaked dialysis membranes and mounted on the receiver compartment of the 
MFDC (Habes, 2005) (see figure(1.8)),  making sure that no bubbles appear. A rubber ring is 
mounted over the membrane to prevent leakage and the donor compartment is mounted over 
the rubber ring. 
The receiver and donor compartments are now separated by the membrane and a clamp is 
used to maintain them in their position while the rubber ring prevents leakage due to pressure 
made by the clamp.  5grams solution or gel to be tested is introduced in the donor 
compartment.  The receiver compartment, the sampling ports and the receiver-donor junction 
were covered with parafilm to assure that no part of the donor or receiver phase is lost. 
A magnetic stirrer is introduced below the MFDC, The water pump and the stirrer is activated 
(zero time for the experiment) (See figure (2.1)). 1ml samples are collected from sampling 
port using a syringe every half an hour for six hours. Before every sample is taken about 
1.5ml from the receiver phase is taken from one port and introduced into the other. This 
process was repeated three times before every sample to ensure that the concentration in the 
ports is the same as in the receiver compartment. 
 After every sample is taken from the cell an equal amount of phosphate buffer (1ml) is 
introduced to the receiver compartment of the MFDC to ensure that its volume is not affected. 
Samples taken were analyzed by HPLC according to USP30 (see section 2.5.4)  and every 
experiment was done in triplicates. The cumulative amount of orphenadrine citrate is 
calculated and plotted versus time, (see section (1.10)), and the diffusion parameter is 
calculated. 
The cumulative amount of the penetrant is calculated according to the following equation:  
Cumulative amount of penetrant at time (t) = Ct × V + 7 89":  
Ct:  is the measured concentration of the penetrant at time t in the receptor compartment in 
mg/ml. 
V: is the volume of the solution in the receiver compartment. 
The thickness of the membrane (h) equals 0.019cm, area of membrane (S) equals 3.14cm2 and 
the volume of the receiver compartment is 25.8ml. 
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Figure 2.1: Modified Franz diffusion cell mounted on a magnetic stirrer and attached to a 
water pump and a water bath. 
 
2.6.5. Calculation of diffusion parameters. 
 
At every sampling time a sample is withdrawn and the amount of orphenadrine citrate is 
determined by HPLC analysis, (see section 2.5.4). A cumulative amount of orphenadrine 
citrate through time is drawn, (see Figure (1.10)), and the diffusion parameters are calculated.  
The curve is extrapolated using Excel 2007  to find the steady state line.  The x intercept of 
the line will be the lag time.
  
According to equation (9) in section (1.9)  
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The slope = PSCd 
Where S is the area, P is the permeability coefficient; Cd is the concentration in the donor 
compartment. 
The permeability coefficient can be calculated as the slope. The area of membrane and 
concentration in donor compartment are known. 
According to equation (12) in section (1.9). 
TL = 


   
Where h is thickness of membrane that was measured during the experiment, TL was 
calculated from the plot so the D the diffusion coefficient  is calculated. 
According to equation (9) 
The permeability coefficient  
 P = 


  
Where h is thickness of membrane that was measured during the experiment, P  is the 
permeability coefficient that was calculated  previously,  and thus the partition coefficient K is 
calculated . 
A summary of the diffusion parameters and their method of calculation is seen in table (2.3) 
 
Table 2.3: Summary of diffusion parameters and their method of calculation 
 
Slope Lag Time(TL) Diffusion 
Coefficient 
Permability 
Coefficient 
Partition 
coefficient 
Enhancement 
ratio 
Calculated from 
the plot 
Intercept with x 
axes 
;!
<=>
 
Slope/Cd ? ;
@
 
Permeability 
with enhancer/ 
permeability 
without 
enhancer 
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2.7. Selecting the best penetration enhancer in solution 
 
To study the effect of penetration enhancers on the permeability of orphenadrine citrate 
through a synthetic membrane, several penetration enhancers were mixed with solution of the 
API and investigated for permeability using MFDC and a synthetic membrane. 
The following PE used are: Propylene glycol, Tween 80, Urea, cremophore RH40, and 
Cyclodextrin. 
An aqueous solution of the API with concentration of 1% is prepared and tested for 
permeability through the synthetic membrane using MFDC. Its diffusion parameters are 
determined and the permeability coefficient is used as a reference to calculate the 
enhancement ratio. 
Each penetration enhancer is mixed with orphenadrine citrate aqueous solution to have a 
solution containing 1% O.C and 1% PE. Then each solution is run through the diffusion 
procedure using the MFDC and the synthetic membrane. The diffusion parameters are 
calculated and the permeability coefficient of the solution with the penetration emhancer is 
compared to the permeability coefficient of solution without penetration enhancer to calculate 
the enhancement ratio. The best penetration enhancer is selected according to the best 
permeability coefficient value. 
 
2.8. Formulating of orphenadrine citrate gel with the best penetration enhancer 
 
Different gel formulas are prepared using the best PE (cremophore RH40), compatible 
excipients and different gelling agents, making sure that the formula is clear, with good 
viscosity, and good spreadability. The formulas are tested for permeability using MFDC 
through a synthetic membrane by the same diffusion procedure mentioned in section 2.6.4. 
The effect of concentration of gelling agent, penetration enhancer, and the effect of the 
amount of gelling agent on drug permeation is determined. The O.C. Gel formulations is 
shown in the next tables. 
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Table 2.4: Gel Formula A 
 
Material Percent w/w Function 
Orphenadrine citrate  1% API 
CMC Na 2% Gelling agent 
Cremophore RH 40 0.2% PE 
Glycerin  5% Enhance Spreadability 
Methyl paraben 0.1% Preservative 
Water To 100g Solvent 
 
Table 2.5: Gel Formula B. 
 
Material Percent w/w Function 
Orphenadrine citrate  1% API 
CMC Na 2% Gelling agent 
Cremophore RH 40 1% PE 
Glycerin  5% Enhance Spreadability 
Methyl paraben 0.1% Preservative 
Water  To 100g Solvent 
 
Formula A and B were formulated with different PE concentrations to determine the effect of 
the PE concentration on drug permeation while other excipients are the same in concentration 
in both formulations. 
The procedure for preparation of the gel formulas A and B is the following : 
Orphenadrine citrate is added to 80 ml water and stirred for 20 minutes until totally dissolved 
with mild heating. Glycerin is added and stirred for 2 minutes,  Cremophore RH 40 is added 
and stirred for 2 minutes. Methyparaben is added and stirred for 20 minutes. The  appropriate 
amount of CMC Na (2g)  is spreaded over the solution and stirred with mild heating for 20 
minutes. Water is added to complete the weight to 100g. The sample is left for 12 hours and 
stirred again for 10 minutes. 
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Table 2.6: Gel Formula C 
 
Material Percent w/w Qt/ grams Function 
Orphenadrine citrate  1% 1 API 
HPMC 3% 3 Gelling agent 
Cremophore RH 40 1% 1 PE 
Glycerin  5% 5 Enhance Spreadability 
Methyl paraben 0.1% 0.1 Preservative 
Water  To 100 g X Solvent 
 
 
Table 2.7: Formula D 
 
Material Percent w/w Qt/ grams Function 
Orphenadrine citrate  1% 1 API 
HPMC 2% 2 Gelling agent 
Cremophore RH 40 1% 1 PE 
Glycerin  5% 5 Enhance Spreadability 
Methyl paraben 0.1% 0.1 Preservative 
Water To 100g X Solvent 
 
 In the Gel Formulas C and D the concentration of O.C, PE and other excipients are the same 
and the only difference is in the gelling agent concentration, these two formulas are used to 
evaluate the effect of viscosity on drug permeation. 
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Table 2.8: Formula E. 
 
Material Percent w/w Qt/grams Function 
Orphenadrine citrate  1% 1 API 
HPMC 3% 3 Gelling agent 
Cremophore RH 40 0.2% 0.2 PE 
Glycerin  5% 5 Enhance Spreadability 
Methyl paraben 0.1% 0.1 Preservative 
Water To 100g X Solvent 
 
In the Gel Formulas C and E the concentration of O.C,  gelling agent and other excipients are 
the same and the only difference is in the PE concentration. These two formulas are used to 
evaluate the effect of the concentration of  PE on the drug permeation. 
The procedure used to prepare the HPMC gel formulas(C, D, E) is as follows: 
Orphenadrine citrate is added to 80 ml water and stirred for 20 minutes until totally dissolved 
with mild heating. Glycerin is added and stirred for 2 minutes. Cremophore RH 40 is added 
and stirred for 2 minutes. Methyparaben is added and stirred for 20 minutes. The appropriate 
amount of HPMC is spreaded over the solution and stirred under mild heat for 10 minutes 
Water is added to complete the weight to 100g; The sample is left for 12 hours and stirred 
again for 10 minutes. 
 
2.9. Determining the effect of different gelling agents on drug permeation 
 
Gel formulas are studied for their permeation through a synthetic membrane using the MFDC 
and the diffusion parameter is determined.  The permeability coefficient is used to determine 
the best gel in synthetic membrane penetration. 
The Permeability coefficient of Formula A (CMC Na as gelling agent) is compared to 
Formula C (HPMC as a gelling agent) and the permeability coefficient of Formula B (CMC 
Na as gelling agent) is compared to the formula D( HPMC as gelling agent).  
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2.10. Determining the effect of viscosity on the drug permeation  
 
The best gel formula is selected according to the best permeability coefficient, the ease of use 
on human skin, and acceptability.( Formulas C and D in section 2.8.) 
The viscosity of the two formulas is determined using a Brookfield viscometer, with spindle 
number 94 at 6 RPM. The formula D was less viscous than Formula C as will be shown in the 
results and discussion part later. The two formulas are studied for permeation using MFDC 
and a synthetic membrane. 
 
 
2.11. Determining the effect of the concentration of penetration enhancer on drug 
permeation. 
 
Formulas C and E (from section 2.8) is studied using a MFDC and a synthetic membrane. The 
diffusion parameters is calculated and compared. 
The gel with the more cremophore RH 40 showed better penetration as expected. 
 
2.12. Studying the permeation of drug through human skin. 
 
Formula C from section 2.8 was selected for permeation study using human skin mounted on 
a MFDC, due to its acceptability, spreadability, and good permeation coefficient. 
The diffusion parameter is determined using MFDC and human stratum corneum. 
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Part 3 
Results and Discussion 
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3.1. Solubility determination results 
 
Saturated solutions of Orphenadrine citrate were prepared at different pHs, their 
concentrations were determined by complexing with trinitrophenol and measuring the 
absorbance at 410 nm (see section 2.5.1). Results are shown in table (3.1). 
 
Table 3.1: The solubility results of orphenadrine citrate in different solutions at 20C. 
 
Orphenadrine citrate in Solubility g/100ml 
Buffer pH 7.4 2.43 
Buffer pH 6 1.63l 
Buffer pH 5 1.39 
Water 1.5 
 
The solubility of orphenadrine citrate increases as the pH increases, the highest solubility was 
found when the pH of the solution was 7.4. 
The solubility of orphenadrine citrate in water was found to be 1 in 70 in accordance with 
values mentioned in the literature (Abate,  et al 2005). 
 
3.2. Studying the compatibility of orphenadrine citrate with excipients and penetration 
enhancers in aqueous solutions. 
 
Different penetration enhancers and exipients were tested for their compatibility with 
orphenadrine citrate in water at different pHs for a period of three months, the results are 
shown in Table (3.2). 
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Table 3.2-A: The results of the compatibility study for three months on 25 C° and 40C°. 
 
Aqueous solution 
% API at 
Zero time 
40 ºC ± 2 ºC (Accelerated Stability Study) 25 ºC ± 2 ºC 
% API after    
1 M 
 
% API after    
2 M 
 
% API after    
3 M 
 
% API after    
3 M 
 
Orphenadrine citrate 
1% 
100% 99% 96% 94% 98% 
Orphenadrine citrate 
1% , carpabol, 
triethanolamine 
 
Non 
compatible 
Non  
compatible 
Non 
compatible 
Non 
compatible 
Non  
Compatible 
Orphenadrine citrate 
1%,  phosphate 
buffer of pH= 7.4 
 
100% 95% X 98% 97.2% 
Orphenadrine citrate 
1% ,  phosphate 
buffer of 
pH= 6 
100% X X 99% 100% 
Orphenadrine citrate 
1% , phosphate 
buffer of 
pH= 5 
100% X 98% X 104% 
Orphenadrine citrate 
1%,  phosphate 
buffer of pH= 5.5 
 
100% X 94% 93% 102% 
Orphenadrine citrate 
1%,  methyl paraben 
 
100% X 97% 93% 102% 
Orphenadrine citrate 
1% , HPMC 
 
100% 94% 94% 90% 99% 
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Table 3.2-B: The results of Compatibility for three months on 25 C° and 40C°. 
 
Aqueous solution 
% API at Zero 
time 
40 ºC ± 2 ºC 25 ºC ± 2 ºC 
% API after    
1 M 
 
% API after    
2 M 
 
% API after    
3 M 
 
% API after    
3 M 
 
Orphenadrine citrate 
1% in water and 
Urea 
100% 25% 25% 17% 102% 
Orphenadrine citrate 
1% in water and 
propylene glycol 
 
100% X 102% 96.8% 101% 
Orphenadrine citrate 
1% in water and 
oleic acid and tween 
80 
 
100% 95% 94% 91% 91% 
Orphenadrine citrate 
1% in water and 
tween 80 
100% 96% 96% 89% 97% 
Orphenadrine citrate 
1% in water and 
sodium 
laurylsulphate 
 
100% X 100% 69% 165% 
Orphenadrine citrate 
1% in water and 
cremophore RH 40 
100% 99% 99% 97% 99% 
Orphenadrine citrate 
1% in water and 
cyclodextrin 
100% 100% 103% 90% 101% 
Orphenadrine citrate 
1% in water and Na 
CMC 
 
 
100% 98% 96.2% 94% 97% 
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Table 3.2-C: The results of Compatibility study for three months on 25 C° and 40C°. 
 
Aqueous solution Zero time 
40 ºC ± 2 ºC 25 ºC ± 2 ºC 
% API after    
1 M 
 
% API after    
2 M 
 
% API after    
3 M 
 
% API after    
3 M 
 
Orphenadrine citrate 
1% in water and Na 
CMC+ glycerin 
100% X X 99% 101% 
 
The (X) letter is used whenever an analysis was not possible. 
When carbopol was added to a solution of orphenadrine citrate a white precipitate was formed 
which indicates that carbopol is incompatible with Orphenadrine citrate and hence cannot be 
used as a gelling agent for formulation. Carbopol is an anionic gelling agent, and it may have 
formed a non soluble complex with Orphenadrine.  
In the presence of urea, the concentration of orphenadrine citrate falls to 17% after 3 months 
of incubation at 40±2°C, while at room temperature no significant change was observed in the 
assay. The presence of heat may result in the hydrolysis of Urea (10% concentration is used) 
and the production of ammonia which may reacts with orphenadrine causing precipitation.  
With Sodium lauryl sulphate the assay of orphenadrine citrate was not stable at 40±2°C. 
Orphenadrine is suggested to form a complex with lauryl sulphate releasing the citrate. This 
complex is not stable at 40 Cº and degrades with time. 
It is clear that orphenadrine citrate is stable over a wide range of pHs (5.0-7.4) which is in 
accordance with the limits of Orphenadrine Citrate Injections pHs (5.0-6.0) approved in USP-
31. The other excipients  (MP, HPMC, CMC Na, Tween 80, Oleic acid, glycerin, 
Cyclodextrin and Propylene glycol), were found to be compatible with OC and may be used 
in the formulation of OC gel 
 
3.3. Determination of best Penetration enhancer in solution. 
 
In this part the lag time (TL) reflects the time required by API to pass through the intact 
membrane and reach to the receiver compartment. Diffusion coefficient (D) measures the 
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membrane resistance encountered by a diffusant. Permeability coefficient (P) gives an 
indication about the distance passed by the substance within specific period. The partition 
coefficient (K) gives an indication about the ability of API to partition between the oily phase 
and aqueous phase, this parameter includes other diffusion parameters as shown in the 
calculation of diffusion parameters (part two). In the final part of this, thesis we made 
attempts to compare the enhancement ratio (ER) of various penetration enhancers used. This 
is a ratio of permeability coefficients constants (P) following the use of penetration enhancer 
divided by the permeability coefficient before the use of penetration enhancer (P after / P 
before). The greater the ER, the greater the penetration enhancement ability of penetration 
enhancer used. 
 
Table 3.3: A list of solutions to be studied for permeability. 
 
Solution no. Composition 
1 Orphenadrine citrate 1% 
2 cremophor RH40 1%, Orphenadrine citrate 1% 
3 Cyclodextrin 1% and orphenadrine 1%  
4 Urea 1% and orphendrine citrate 1% in water 
5 Tween 80 1% and orphenadrine citrate 1% 
6 Propylene glycol 1%,  orphenadrine citrate 1% 
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3.3.1. Solution No. 1  Orphenadrine citrate 1% and Water 
 
For the preparation of Orphenadrine citrate 1% in water, 1g of O.C was dissolved in 80ml of 
water by the aid of sonicator for 10 minutes; the volume was made up to 100ml with water 
and mixed.  
Samples are taken every 30 minutes from the receiver compartment and analyzed by HPLC 
for the amount of orphenadrine citrate.  
Table (3.4) illustrates the assay results of API penetrated to the receiving compartment by time. 
Area under peaks (Area1, Area2, Area3)  was presented in triplicates, and the cumulative amount of 
drug penetrated (Q) per unit of membrane area was determined and plotted as a function of time 
Fig. (3-1). The linear part of the curve was plotted in Fig. (3.2) from which the diffusion parameters 
were calculated for API alone and tabulated in Table (3-4). The TL was calculated by dividing the 
intercept of the equation of flux profile on the slope from the same equation. The diffusion 
parameter (D) was calculated using equation 1: 
 
D = h2/6.Tl               (1) 
 
The permeability coefficient (P) was calculated by dividing the value of the slope of the flux profile 
by the concentration of API in the donor compartment (10mg/ml). The permeability coefficient (p) 
was used here as the main value in the comparison between the activity of different penetration 
enhancers, since its value was obtained from all diffusion parameters as shown in equation 2. 
 
K = (P. h) / D            (2) 
. 
 
. 
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Table 3.4: Data obtained from the diffusion of solution No. 1 through a synthetic membrane using a Modified Franz diffusion cell, 
with no penetration enhancer introduced. 
 
 
 
 
Hrs Area 1 Area 2 Area 3 
Mean 
Area 
SD RSD 
Amount 
mg/ml 
mg/25.8ml Q [mg] 
m 
[mg/cm2] 
0.0 0 0 0 0 0 0 0 0 0 0 
1.0 1294138 1517924 2903885 1905316 871995 45.8 0.0321 0.8286 0.8286 0.2639 
1.5 1777708 2152610 4128733 2686350 1263127 47.0 0.0453 1.1682 1.2003 0.3823 
2.0 2150727 2881389 5077651 3369922 1523391 45.2 0.0568 1.4655 1.5107 0.4811 
2.5 2494094 3429543 5881011 3934883 1749093 44.5 0.0663 1.7112 1.7680 0.5630 
3.0 2877533 3950219 6337057 4388270 1770873 40.4 0.0740 1.9083 1.9746 0.6289 
3.5 3315750 4707504 7365077 5129444 2057374 40.1 0.0865 2.2306 2.3046 0.7339 
4.0 3596938 5327683 7896880 5607167 2163552 38.6 0.0945 2.4384 2.5248 0.8041 
4.5 3918197 5833517 8969353 6240356 2550036 40.9 0.1052 2.7137 2.8082 0.8943 
5.0 4274966 6477851 9620921 6791246 2686721 39.6 0.1145 2.9533 3.0585 0.9740 
5.5 4612057 7136978 10532922 7427319 2971091 40.0 0.1252 3.2299 3.3444 1.0651 
6.0 5173753 7932375 11526897 8211008 3185724 38.8 0.1384 3.5707 3.6959 1.1770 
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Table (3.4) shows the assay results of orphenadrine citrate, this diffusion study was done three 
times.  The cumulative amount of orphenadrine citrate per unit of membrane area was calculated 
and plotted as a function of time. See figure (3.1).  
 
 
 
Figure 3.1: In vitro permeation profile for the cumulative amount of O.C penetrated per unit area 
of synthetic membrane (mg/cm²) for solution no. 1, with no penetration enhancer 
 
The best linear line is determined on figure (3.2) by Excel 2007, from which the linear line 
equation is determined. This equation helps in determining the slope and the x intercept; these 
are used for further calculation of diffusion parameters. The diffusion parameters are calculated 
according to table (2.3).  
The steady state Flux diagram and the diffusion parameters are shown in figure (3.2) and table 
(3.5). 
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Figure 3.2: Linear In vitro flux diagram for the cumulative amount of O.C penetrated per unit 
area of synthetic membrane (mg/cm²) for solution no. 1 with no penetration enhancer. 
. 
 
Table 3.5: Diffusion parameters for solution no. 1, no penetration enhancer introduced. 
 
Item Slope Intercept TL D P K ER 
API 0.174 0.126 0.644h 0.0000534 0.0112 3.96 1.00 
 
The permeability parameter of this solution is used as a reference for penetration enhancement 
comparison.  
Orphenadrine citrate solution showed some penetration through the synthetic membrane due to 
its solubility in hydrophilic and hydrophobic parts of the synthetic membrane. 
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3.3.2. Solution 2  Orphenadrine citrate 1% and cremophore RH40 1% penetration 
enhancer in water 
 
Cremophore RH40 is a Polyoxyethylene castor oil derivative of complex mixtures of various 
hydrophobic and hydrophilic components. Approximately 75% of the components of the mixture 
are hydrophobic. These comprise mainly fatty acid esters of glycerol, polyethylene glycol and 
fatty acid esters of polyethylene glycol. The hydrophilic portion consists of polyethylene glycols 
and glycerol ethoxylates.( Rowe, 2005). It is an Emulsifying agent, solubilizing agent and 
wetting agent. It can be used for oral and topical preperations. ( Rowe, 2005). 
A solution of orphenadrine citrate 1% was prepared by dissolving 1g of O.C in 80g of water, 
Cremophore RH40 1g is added, stirred and the volume is made up to 100ml. The permeability 
results of drug through the synthetic membrane is shown in table (3.6) and Fig. (3.3).  
The cumulative amount of API permeated through unit area of membrane was then calculated as 
mentioned before, and the linear section, i.e. the steady state flux was plotted versus time Fig. (3.4).  
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Table 3.6: Data obtained by the diffusion of solution No. 2 through a synthetic membrane, using a Modified Franz diffusion cell, and 
cremophor RH40 as a penetration enhancer. 
 
 
hrs Area 1 
Amount1 
mg/ml 
Area 2 
Amount2 
mg/ml 
Area 3 
Amoun3 
mg/ml 
Mean 
mg/ml 
SD RSD 
cumulative 
mg/ml 
mg/25.8ml Q [mg] 
m 
[mg/cm2] 
0.0 0 0 0  0 0 0 0 0 0 0 0 0 
1.0 5489846 0.0934 1293549 0.0248 1730899 0.0332 0.0504 0.0374 74.1 0.0504 1.3015 1.3015 0.4145 
1.5 7865607 0.1338 2303759 0.0442 2981187 0.0571 0.0784 0.0484 61.8 0.1288 2.0216 2.0720 0.6599 
2.0 8884861 0.1511 3278716 0.0629 4221800 0.0809 0.0983 0.0466 47.4 0.2270 2.5359 2.6646 0.8486 
2.5 10976152 0.1867 4799678 0.0920 5446122 0.1044 0.1277 0.0514 40.3 0.3547 3.2943 3.5213 1.1214 
3.0 12855829 0.2186 6830268 0.1309 7392471 0.1417 0.1638 0.0478 29.2 0.5185 4.2248 4.5795 1.4585 
3.5 15042933 0.2558 9400958 0.1802 11519899 0.2208 0.2189 0.0378 17.3 0.7374 5.6489 6.1674 1.9641 
4.0 15886153 0.2701 12507328 0.2398 15195174 0.2913 0.2671 0.0259 9.7 1.0045 6.8902 7.6276 2.4292 
4.5 17476605 0.2972 16311802 0.3127 22095085 0.4235 0.3445 0.0689 20.0 1.3490 8.8875 9.8920 3.1503 
5.0 19116998 0.3251 20518380 0.3933 29188624 0.5595 0.4260 0.1206 28.3 1.7750 10.9903 12.3393 3.9297 
5.5 20627842 0.3508 25187124 0.4828 36070242 0.6914 0.5083 0.1718 33.8 2.2833 13.1154 14.8903 4.7421 
6.0 22464336 0.3820 30469215 0.5841 42565213 0.8159 0.5940 0.2171 36.6 2.8773 15.3255 17.6088 5.6079 
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In vitro permeation profile for the cumulative amount of O.C penetrated per unit area for solution 
no.2 is shown in figure (3.3); the Steady state flux diagram is shown in figure (3.4) 
 
 
 
 
Figure 3.3: In vitro permeation profile for the cumulative amount of O.C penetrated per unit area 
of synthetic membrane (mg/cm²) for solution no. 2, Cremophor RH40 is used as a penetration 
enhancer.  
 
.  
 
Figure 3.4: In vitro Steady steady permeation profile for the cumulative amount of O.C 
penetrated per unit area of synthetic membrane (mg/cm²) for solution no. 2, Cremophor RH40 is 
used as a penetration enhancer. 
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The diffusion parameters are calculated according to table (2.3) and the enhancement ratio is 
determined. (See table 3.6). 
 
Table 3.7: Diffusion parameters for solution no.2. Cremophor RH40 is used as a penetration 
enhancer. 
 
Item Slope Intercept TL D P K ER 
API 1.296 2.458 1.89 h 0.0000318 0.1269 77.43 11.33 
 
The rate of diffusion of API in the presence of Cremophor RH40 is faster than when it is alone, 
this is indicated by the value of high permeability coefficient (P) from which the enhancement 
ratio (ER) is found to be (11.33). 
This great value of permeation coefficient of Cremophor RH40 is probably due to its ability to 
create miniscule holes in the intact membrane by removing some parts of oil through which the 
API can shuttle. 
 
3.3.3. Solution No. 3 Cyclodextrin 1% and orphenadrine 1% in water 
Cyclodextrins are crystalline, nonhygroscopic, cyclic oligosaccharides (7 glucose units) derived 
from starch. Cyclodextrins are ‘bucketlike’ or ‘conelike’ toroid molecules, with a rigid structure 
and a central cavity. The internal surface of the cavity is hydrophobic and the outside of the torus 
is hydrophilic; this is due to the arrangement of hydroxyl groups within the molecule. This 
arrangement permits the cyclodextrin to accommodate a guest molecule within the cavity, 
forming an inclusion complex. Cyclodextrins may be used to form inclusion complexes with a 
variety of drug molecules, resulting primarily in improvements to dissolution and bioavailability 
owing to enhanced solubility and improved chemical and physical stability ( Rowe, 2005). 
Using -cyclodextrin 1% as potential penetration enhancer and following the same general 
procedure, the data measured are shown in table (3.8). 
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Table 3.8: Data obtained by the diffusion of solution No. 3, Using Cyclodextrin as penetration enhancer. 
 
 
 
 
hrs Area 1 Amount1 
mg/ml 
Area 2 Amount2 
mg/ml 
Area 3 Amoun3 
mg/ml 
Mean 
mg/ml 
SD RSD cumulative 
mg/ml 
mg/25.8ml Q 
[mg] 
m 
[mg/cm2] 
0.0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1.0 3194707 0.0561 1663511 0.0319 492408 0.0094 0.0325 0.0233 71.9 0.0325 0.8380 0.8380 0.2669 
1.5 4319249 0.0759 2205082 0.0423 810020 0.0155 0.0446 0.0302 67.9 0.0771 1.1495 1.1820 0.3764 
2.0 5433989 0.0954 2809820 0.0539 1151436 0.0221 0.0571 0.0368 64.4 0.1342 1.4739 1.5509 0.4939 
2.5 6434722 0.1130 4540559 0.0870 1684304 0.0323 0.0775 0.0412 53.2 0.2116 1.9982 2.1324 0.6791 
3.0 7522734 0.1321 6055446 0.1161 2212421 0.0424 0.0969 0.0478 49.4 0.3085 2.4994 2.7110 0.8634 
3.5 8348101 0.1466 7864420 0.1508 2766066 0.0530 0.1168 0.0553 47.3 0.4253 3.0135 3.3221 1.0580 
4.0 9599551 0.1686 9829646 0.1884 3317956 0.0636 0.1402 0.0671 47.8 0.5655 3.6176 4.0429 1.2875 
4.5 10106399 0.1775 11735205 0.2250 4218305 0.0809 0.1611 0.0734 45.6 0.7266 4.1567 4.7222 1.5039 
5.0 11338049 0.1992 12601477 0.2416 4956821 0.0950 0.1786 0.0754 42.2 0.9052 4.6073 5.3339 1.6987 
5.5 12451307 0.2187 14097264 0.2702 5727370 0.1098 0.1996 0.0819 41.0 1.1048 5.1491 6.0543 1.9281 
6.0 12851639 0.2257 16200048 0.3105 6773976 0.1299 0.2220 0.0904 40.7 1.3268 5.7288 6.8335 2.1763 
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In vitro permeation profile for the cumulative amount of O.C penetrated per unit area for solution 
no3 is shown in figure (3.5); the Steady state diagram is shown in figure (3.6) 
 
 
 
Figure 3.5 : In vitro permeation profile for the cumulative amount of O.C penetrated per unit area 
of synthetic membrane (mg/cm²) for solution no.3, using Cyclodextrin as penetration enhancer 
 
 
 
 
Figure 3.6: In Steady state vitro permeation profile for the cumulative amount of O.C penetrated 
per unit area for solution no3, using Cyclodextrin as penetration enhancer. 
	 	
	
	
	
	
	
	
	
	 	 	 	 	
   
	 

	 	
	
	
	
	
	
	
	
	 	 	 	 	 	 	 
	
   
	 

58 
 
Table 3.9: Diffusion parameters for solution no.3, using Cyclodextrin is used as a penetration 
enhancer. 
 
Item Slope Intercept TL D P K ER 
API 1.296 0.380 0.9 hh 0.0000669 0.0419 11.9 3.74 
 
The calculated enhancement ratio for -cyclodextrin was more than triple, but not to the extent of 
Cremophor RH40,.   
 
3.3.4. Solution no. 4 Urea 1% and orphendrine citrate 1% in water 
 
Urea promotes transdermal permeation by facilitating hydration of the stratum corneum and by 
the formation of hydrophilic diffusion channels within the barrier. 
The data of HPLC analysis of solution no. 4 is shown in table (3.10) The cumulative amount of 
O.C penetrated per unit area is shown in figure (3.7); the Steady state flux diagram is shown in 
figure (3.8) 
The enhancement ratio of Urea was found to lie between Cremophor RH 40 and -cyclodextrin. 
The calculated diffusion parameters are presented in table (3.11).  
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Table 3.10: Data obtained by the diffusion of solution No. 4 through a synthetic membrane using a Modified Franz diffusion cell. Urea 
is used as penetration enhancer. 
 
hrs Area 1 Amount1 
mg/ml 
Area 2 Amount2 
mg/ml 
Area 3 Amoun3 
mg/ml 
Mean 
mg/ml 
SD RSD cumulative 
mg/ml 
mg/25.8ml Q 
[mg] 
m 
[mg/cm2] 
0.0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1.0 1635010 0.0278 3109159 0.0554 2848654 0.0507 0.0446 0.0148 33.1 0.0446 1.1514 1.1514 0.3667 
1.5 2530591 0.0430 4891549 0.0938 4520314 0.0805 0.0724 0.0263 36.3 0.1170 1.8687 1.9133 0.6093 
2.0 3480743 0.0592 6714606 0.1287 6181406 0.1101 0.0993 0.0360 36.2 0.2164 2.5625 2.6795 0.8534 
2.5 4246353 0.0722 8338956 0.1599 8092108 0.1441 0.1254 0.0467 37.3 0.3417 3.2348 3.4512 1.0991 
3.0 4953174 0.0842 10030286 0.1923 9230824 0.1644 0.1470 0.0561 38.2 0.4887 3.7914 4.1331 1.3163 
3.5 5495417 0.0935 11644495 0.2232 10573876 0.1883 0.1683 0.0671 39.9 0.6570 4.3425 4.8311 1.5386 
4.0 6187368 0.1052 12935269 0.2480 11681390 0.2080 0.1871 0.0736 39.4 0.8441 4.8260 5.4830 1.7462 
4.5 6681278 0.1136 14314367 0.2744 12973600 0.2310 0.2063 0.0832 40.3 1.0504 5.3235 6.1675 1.9642 
5.0 7289575 0.1240 15492687 0.2970 14129198 0.2516 0.2242 0.0897 40.0 1.2746 5.7836 6.8340 2.1764 
5.5 8037361 0.1367 16799356 0.3220 15372173 0.2737 0.2441 0.0961 39.4 1.5187 6.2987 7.5733 2.4119 
6.0 8977908 0.1527 17963476 0.3443 16443073 0.2928 0.2633 0.0992 37.7 1.7820 6.7922 8.3109 2.6468 
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Figure 3.7: In vitro permeation profile for the cumulative amount of O.C penetrated per unit area 
of synthetic membrane (mg/cm²) for solution no. 4, using urea as penetration enhancer. 
 
 
 
 
 
Figure 3.8: In vitro Steady state permeation profile for the cumulative amount of O.C penetrated 
per unit area of synthetic membrane (mg/cm²) for solution no. 4, using urea as penetration 
enhancer. 
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Table 3.11: Diffusion parameters for solution number 4, using Urea as a penetration enhancer. 
 
Item Slope Intercept TL D P K ER 
API 0.449 0.053 0.118 0.000510 0.0449 1.67 4.01 
 
 
3.3.5. Solution no. 5 Tween 80 1% and orphenadrine citrate 1% in water 
 
The effect of nonionic surfactant Tween 80 in amount of 1% on the permeation of API is 
presented in table (3.12). The cumulative amount of O.C penetrated per unit area and Steady 
state flux diagram are figures (3.9) and (3.10), respectively. 
The diffusion parameters are presented in table (3.13) 
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Table 3.12: Data obtained by the diffusion of solution No. 5 through a synthetic membrane using a Modified Franz diffusion cell. 
Tween 80 is used as a penetration enhancer. 
 
 
hrs Area 1 Amount1 
mg/ml 
Area 2 Amount2 
mg/ml 
Area 3 Amoun3 
mg/ml 
Mean 
mg/ml 
SD RSD cumulative 
mg/ml 
mg/25.8ml Q [mg] m  
[mg/cm2] 
0.0 0 0 0  0 0 0 0 0 0 0 0 0 
1.0 3563634 0.0626 1300536 0.0232 1300536 0.0232 0.0363 0.0228 62.7 0.0363 0.9366 0.9366 0.2983 
1.5 4602857 0.0808 2061750 0.0367 2061750 0.0367 0.0514 0.0255 49.6 0.0877 1.3267 1.3630 0.4341 
2.0 5774812 0.1014 2810767 0.0500 2810767 0.0500 0.0672 0.0297 44.2 0.1549 1.7331 1.8208 0.5799 
2.5 7368450 0.1294 3564058 0.0635 3564058 0.0635 0.0854 0.0381 44.6 0.2403 2.2045 2.3594 0.7514 
3.0 8608224 0.1512 4329833 0.0771 4329833 0.0771 0.1018 0.0428 42.0 0.3421 2.6263 2.8667 0.9130 
3.5 9810147 0.1723 5178468 0.0922 5178468 0.0922 0.1189 0.0463 38.9 0.4610 3.0678 3.4099 1.0860 
4.0 11321277 0.1989 5900220 0.1051 5900220 0.1051 0.1363 0.0542 39.7 0.5974 3.5171 3.9781 1.2669 
4.5 12528679 0.2201 6688859 0.1191 6688859 0.1191 0.1528 0.0583 38.2 0.7501 3.9410 4.5384 1.4453 
5.0 13651980 0.2398 7746557 0.1379 7746557 0.1379 0.1719 0.0588 34.2 0.9220 4.4346 5.1847 1.6512 
5.5 14690766 0.2580 8239991 0.1467 8239991 0.1467 0.1838 0.0643 35.0 1.1058 4.7426 5.6646 1.8040 
6.0 15796869 0.2775 9317057 0.1659 9317057 0.1659 0.2031 0.0644 31.7 1.3089 5.2395 6.3454 2.0208 
63 
 
 
 
Figure 3.9: In vitro permeation profile for the cumulative amount of O.C penetrated per unit area 
of synthetic membrane (mg/cm²) for solution no.5, using Tween 80 as a penetration enhancer. 
 
 
 
 
Figure 3.10: In vitro steady state flux diagram of orphenadrine citrate (mg/cm2) through a 
synthetic membrane for solution no. 5., using Tween 80 used as a penetration enhancer. 
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Table: 3.13: Diffusion parameters for solution no. 5, using  Tween80 as a penetration enhancer. 
 
Item Slope Intercept TL D P K ER 
API 0.358 0.154 0.43 h 0.000140 0.0358 4.86 3.20 
 
 
3.3.6. Solution no. 6 Propylene glycol 1% and orphenadrine citrate 1% in water 
 
 In general propylene glycol increases the permeant partitioning and solubility within the stratum 
corneum. 
The data obtained from the diffusion study of solution No.6 is presented in table (3.14), the 
cumulative amount of O.C penetrated per unit area is calculated and presented in figure (3.11); 
the Steady state flux diagram is shown in figure (3.12). The diffusion parameters are tabulated in 
table (3.15). It is obvious that propylene glycol has the lowest effcet on penetration 
enhancement, increasing the percentage of Propylene glycol to 10% caused a total blockage of 
penetration. 
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Table 3.14 : Data obtained by the diffusion of solution No. 6 through a synthetic membrane using a Modified Franz diffusion cell. 
Using propylene glycol. 
 
 hrs Area 1 Area 2 Area 3 Mean SD RSD mg/ml cumulative 
mg/ml 
mg/25.8ml Q [mg] m 
[mg/cm2] 
0.0 0 0 0 0 0 0 0 0 0 0 0 
1.0 937953 607549 277145 607549 330404 54.4 0.0116 0.0116 0.3005 0.3005 0.0957 
1.5 1077802 796946 516089 796946 280857 35.2 0.0135 0.0251 0.3481 0.3597 0.1146 
2.0 1302541 1048965 795388 1048965 253577 24.2 0.0178 0.0429 0.4582 0.4833 0.1539 
2.5 1852615 1480579 1108543 1480579 372036 25.1 0.0251 0.0680 0.6467 0.6896 0.2196 
3.0 2585932 1987897 1389861 1987897 598036 30.1 0.0337 0.1016 0.8683 0.9363 0.2982 
3.5 3462287 2620584 1778880 2620584 841704 32.1 0.0444 0.1460 1.1447 1.2463 0.3969 
4.0 4291869 3227101 2162333 3227101 1064768 33.0 0.0546 0.2006 1.4096 1.5556 0.4954 
4.5 5309112 3893464 2477815 3893464 1415649 36.4 0.0659 0.2665 1.7006 1.9013 0.6055 
5.0 6490985 4717606 2944226 4717606 1773380 37.6 0.0799 0.3464 2.0606 2.3272 0.7411 
5.5 7854147 5750400 3646652 5750400 2103748 36.6 0.0974 0.4438 2.5117 2.8581 0.9102 
6.0 8210189 6077263 3944336 6077263 2132927 35.1 0.1029 0.5466 2.6545 3.0983 0.9867 
66 
 
 
 
 
Figure 3.11: In vitro permeation profile for the cumulative amount of O.C penetrated per unit 
area of synthetic membrane (mg/cm²) for solution no. 6, using propylene glycol as penetration 
enhancer. 
 
 
 
Figure 3.12: In vitro steady state flux diagram of orphenadrine citrate (mg/cm²) through a 
synthetic membrane for solution no. 6, using propylene glycol as penetration enhancer. 
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Table: 3.15: Diffusion parameters for solution no. 6, using Propylene glycol as a penetration 
enhancer. 
 
Item Slope Intercept TL D P K ER 
API 0.238 0.154 1.84 h 0.0000327 0.0238 13.8 2.13 
 
 
3.4. Gel Permeation study using a MFDC and the best penetration enhancer “Cremophor 
RH40” and a synthetic membrane. 
 
The recovered amounts of API in the receiver compartment from Gel no.1 by time are illustrated 
in table (3.16). 
The cumulative amount and flux diagram are shown in figure (3.13), (3.14) respectively.  
This gel formula (Permeability coefficient) was considered a reference for other CMC Na. gel 
formulations to compare with. That is the enhancement ratio of this gel is 1.  
 
3.4.1 Gel Formulas using CMC Na as gelling agent. 
 
3.4.1.1 Gel no. 1: Orphenarine citrate 1%, Cremophore RH40 0.2%, CMC Na 2%, glycerin 
5%, methyl paraben 0.1% 
 
The recovered amounts of API in the receiver compartment from Gel no.1 by time are illustrated 
in table (3.16). 
The cumulative amount and flux diagram are shown in figure (3.13), (3.14) respectively.  
This gel formula (Permeability coefficient) was considered a reference for other CMC Na. gel 
formulations to compare with. That is the enhancement ratio of this gel is 1.  
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Table 3.16: Data obtained by the diffusion of gel No. 1 through a synthetic membrane using a 
Modified Franz diffusion cell. Cremophore RH40 0.2%  is used as a penetration enhancer , CMC 
Na as gelling agent. 
 
hrs Area mg/ml cumulative 
mg/ml 
mg/25.8ml Q [mg] m [mg/cm2] 
0.0 0.000 0 0 0 0 0 
1.0 2.004 0.0058 0.0058 0.1493 0.1493 0.0476 
1.5 2.892 0.0084 0.0141 0.2155 0.2213 0.0705 
2.0 3.821 0.0110 0.0252 0.2847 0.2989 0.0952 
2.5 4.717 0.0136 0.0388 0.3515 0.3767 0.1200 
3.0 5.652 0.0163 0.0551 0.4212 0.4600 0.1465 
3.5 6.342 0.0183 0.0734 0.4726 0.5277 0.1681 
4.0 7.405 0.0214 0.0948 0.5518 0.6252 0.1991 
4.5 8.104 0.0234 0.1182 0.6039 0.6987 0.2225 
5.0 8.939 0.0258 0.1441 0.6661 0.7843 0.2498 
5.5 9.795 0.0283 0.1723 0.7299 0.8739 0.2783 
6.0 10.578 0.0306 0.2029 0.7882 0.9606 0.3059 
 
 
 
 
Figure 3.13: In vitro permeation profile for the cumulative amount of O.C penetrated per unit 
area of synthetic membrane (mg/cm²) for gel no. 1. Cremophor RH 40 0.2% was used as a 
penetration enhancer, and CMC Na 2% as gelling agent. 
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Figure 3.14: In vitro steady state flux diagram of orphenadrine citrate (mg/cm²) through a 
synthetic membrane for gel no. 1. Cremophor RH 40 0.2% was used as a penetration enhancer 
and CMC Na 2% as gelling agent  
 
Table 3.17: Diffusion parameters for gel no. 1. Cremophor RH 40 0.2% was used as a 
penetration enhancer and CMC Na 2% as gelling agent  
 
Gelling 
Agent 
PE Slope TL D P K ER 
CMC 
Sodium 
0.2% Cremophor RH40 0.005 0.2 0.000301 0.0005 0.0316 1.00 
 
The concentration of the penetration enhancer cremophore RH40 was kept as low as possible to 
give an acceptable gel formulation. 
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3.4.1.2. Gel no. 2: Orphenarine citrate 1%, Cremophore RH40 1%, CMC Na 2%, glycerin 
5%, methyl paraben 0.1% 
 
Table 3.18: Data obtained by the diffusion of gel No. 2 through a synthetic membrane using a 
Modified Franz diffusion cell. Cremophore RH40 1%  is used as a penetration enhancer and 
CMC Na 2% as a gelling agent. 
 
Area mg/ml cumulative 
mg/ml 
mg/25.8ml Q [mg] m [mg/cm2] 
0.000 0 0 0 0 0 
4.977 0.0015 0.0015 0.0389 0.0389 0.0124 
8.662 0.0026 0.0041 0.0677 0.0692 0.0220 
10.660 0.0032 0.0074 0.0833 0.0874 0.0278 
10.926 0.0033 0.0107 0.0854 0.0928 0.0295 
12.007 0.0036 0.0143 0.0938 0.1045 0.0333 
13.276 0.0040 0.0183 0.1038 0.1181 0.0376 
14.545 0.0044 0.0227 0.1137 0.1320 0.0420 
16.161 0.0049 0.0276 0.1263 0.1490 0.0475 
18.676 0.0057 0.0333 0.1460 0.1736 0.0553 
20.544 0.0062 0.0395 0.1606 0.1939 0.0617 
22.920 0.0069 0.0465 0.1791 0.2186 0.0696 
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Figure 3.15: In vitro permeation profile for the cumulative amount of O.C penetrated per unit 
area of synthetic membrane (mg/cm²) for gel no. 2. Cremophore RH40 1%  is used as a 
penetration enhancer and CMC Na 2% as a gelling agent. 
 
 
 
Figure 3.16: In vitro steady state flux diagram of orphenadrine citrate (mg/cm²) through a 
synthetic membrane for gel no.2. Cremophore RH40 1%  is used as a penetration enhancer and 
CMC Na 2% as a gelling agent. 
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Table: 3.19: Diffusion parameters for gel no. 2. Cremophore RH40 1% is used as a penetration 
enhancer and CMC Na 2% as a gelling agent. 
 
 
Gelling 
Agent 
PE Slope TL D P K ER 
CMC 
Sodium 
1 % Cremophor RH40 0.0113 1.1 h 0.0000547 0.00113 0.0316 2.26 
 
 
Increasing the concentration of penetration enhancer from 0.2% to 1% increased the permeability 
of the gel  
 
3.4.2. Gels using HPMC as gelling agent 
 
3.4.2.1. Gel no. 3:  HPMC 3%+ cremophore 0.2%+orphendrine citrate 1%+ glycerine 
5%+Methyl paraben 0.1% 
 
This gel formula is considered a reference for other gel formulas that use the same gelling agent 
(HPMC), that is the enhancement ratio is one. 
In this formula the concentration of Cremophor was kept as low as possible to have an 
acceptable gel formula. 
The data collected is presented in table (3.20). The steady state  flux diagram is shown in figure 
(3.17) and the diffusion parameters are calculated in table (3.21). 
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Table 3.20: Data obtained by the diffusion of gel No. 3 through a synthetic membrane using a 
Modified Franz diffusion cell. Cremophore RH40 0.2%  is used as a penetration enhancer and 
HPMC 3% as gelling agent. 
 
hrs Area mg/ml cumulative 
mg/ml 
mg/25.8ml Q [mg] m [mg/cm2] 
0.0 0.000 0 0 0 0 0 
1.0 3.438 0.0010 0.0010 0.0262 0.0262 0.0083 
1.5 5.316 0.0016 0.0026 0.0405 0.0415 0.0132 
2.0 7.436 0.0022 0.0048 0.0566 0.0592 0.0189 
2.5 10.055 0.0030 0.0077 0.0765 0.0813 0.0259 
3.0 11.886 0.0035 0.0113 0.0905 0.0982 0.0313 
3.5 14.000 0.0041 0.0154 0.1066 0.1178 0.0375 
4.0 15.927 0.0047 0.0201 0.1213 0.1366 0.0435 
4.5 18.008 0.0053 0.0254 0.1371 0.1572 0.0501 
5.0 19.779 0.0058 0.0312 0.1506 0.1760 0.0560 
5.5 21.890 0.0065 0.0377 0.1667 0.1979 0.0630 
6.0 24.246 0.0072 0.0448 0.1846 0.2223 0.0708 
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Figure 3.17: In vitro steady state flux for the cumulative amount of O.C penetrated per unit area 
of synthetic membrane (mg/cm²) for gel no.3. Cremophore RH40 0.2% is used as a penetration 
enhancer and HPMC 3% as gelling agent. 
 
Table 3.21: Diffusion parameters for gel no.3. Cremophore RH40 0.2%  is used as a penetration 
enhancer and HPMC 3% as gelling agent. 
 
Gelling 
Agent 
PE Slope TL D P K ER 
HPMC 3% Cremophor RH40 0.2% 0.012 0.416 0.000145 0.0012 0.066 1 
 
 
3.4.2.2: Gel no. 4:  HPMC 3%+ cremophore 1%+orphendrine citrate 1%+ glycerine5% + 
Methyl paraben 0.1% 
 
This study was repeated two times using a MFDC. The data are shown in table (3.22). 
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Table 3.22: Data obtained by the diffusion of gel No. 4 through a synthetic membrane using a 
Modified Franz diffusion cell. Cremophor RH40 1%  is used as a penetration enhancer and 
HPMC 3% as gelling agent 
 
hrs Amount1 
mg/ml 
Amount2 
mg/ml 
Mean 
mg/ml 
cumulative 
mg/ml 
mg/25.8ml Q 
[mg] 
m 
[mg/cm2] 
0.0 0 0  0 0 0 0 
1.0 0.0014 0.0017 0.0015 0.0015 0.0398 0.0398 0.0127 
1.5 0.0022 0.0029 0.0026 0.0041 0.0664 0.0679 0.0216 
2.0 0.0032 0.0050 0.0041 0.0082 0.1060 0.1102 0.0351 
2.5 0.0042 0.0092 0.0067 0.0149 0.1730 0.1812 0.0577 
3.0 0.0050 0.0127 0.0088 0.0238 0.2279 0.2428 0.0773 
3.5 0.0059 0.0152 0.0106 0.0343 0.2727 0.2964 0.0944 
4.0 0.0068 0.0191 0.0129 0.0473 0.3341 0.3684 0.1173 
4.5 0.0077 0.0233 0.0155 0.0627 0.3990 0.4463 0.1421 
5.0 0.0085 0.0274 0.0179 0.0807 0.4628 0.5255 0.1674 
5.5 0.0092 0.0339 0.0215 0.1022 0.5548 0.6355 0.2024 
6.0 0.0101 0.0373 0.0237 0.1259 0.6109 0.7130 0.2271 
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Figure 3.18: In vitro permeation profile for the cumulative amount of O.C penetrated per unit 
area of synthetic membrane (mg/cm²) for gel no. 4. Cremophor RH40 1%  is used as a 
penetration enhancer and HPMC 3% as gelling agent 
 
 
 
Figure 3.19: In vitro steady state flux diagram of orphenadrine citrate (mg/cm²) through a 
synthetic membrane for gel no. 4. Cremophor RH40 1% is used as a penetration enhancer and 
HPMC 3% as gelling agent 
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Table 3.23: Diffusion parameters of gel no.4. Cremophor RH40 1% is used as a penetration 
enhancer and HPMC 3% as gelling agent 
 
Gelling 
Agent 
PE Slope TL D P K ER 
HPMC 3% Cremophor RH40 1% 0.047 1.4 h 0.0000429 0.0047 2.1 3.9 
 
 
Increasing the concentration of Cremophor RH40 to 1% resulted in about 4-fold penetration 
enhancement of the API. 
 
3.5. The effect of gelling agent and the concentration of penetration enhancer on API 
permeability 
 
The diffusion parameters and the permeability coefficients of  gels numbers 1, 2, 3, and 4 are 
shown in table (3.24). Considering gel no. 1 as a reference with enhancement ratio equals one. 
The enhancement ratio is calculated by dividing the permeability of the gel over the permeability 
of gel no. 1. 
 
Table 3.24: Summary of the Diffusion results for gels numbers 1, 2, 3, and 4. Cremophor RH40 
was used as penetration enhancer, HPMC and CMC Na as gelling agents. 
 
Gel no. Gelling 
Agent 
PE 
Conc. 
TL D P K ER 
1 CMC Na. 2% 0.2% 0.2 0.0003010 0.00050 0.0316 1.0 
2 CMC Na 2% 1% 1.1 h 0.0000547 0.00113 0.0316 2.3 
3 HPMC 3% 0.2% 0.4 0.0001450 0.00120 0.0660 2.4 
4 HPMC 3% 1% 1.4 h 0.0000429 0.00470 2.1000 9.4 
 
78 
 
When concentration of penetration enhancer is equal and the only difference is the type of 
gelling agent, HPMC showed a better permeation results than CMC Na. 
The HPMC gel formula no. 4 is selected for further diffusion study on human skin. 
 
3.6. The effect of viscosity on the permeation of API through a synthetic membrane using a 
MFDC. 
 
To study the effect viscosity on API diffusion through a synthetic membrane, a new formula is 
prepared with less viscosity than gel no. 4 and the permeability coefficient is determined. 
The permeability coefficient of gel no.4 is used as a reference, that is the permeability coefficient 
is one. 
Gel formula no. 5: HPMC 2%, Cermophor 1%, orphenadrine citrate 1%, glycerin 5%, 
methyl paraben 0.1%: Viscosity 7×10³ cps 
The gel formula no. 5 is studied for diffusion through a synthetic membrane using a MFDC. The 
data are shown in table (3.25) . 
  
Table 3.25: Data obtained by the diffusion of gel No. 5 through a synthetic membrane cell, using 
HPMC 2% as gelling agent and Cremophor RH40 1% as a penetration enhancer 
hrs Area mg/ml cumulative 
mg/ml 
mg/25.8ml Q [mg] m 
[mg/cm2] 
0.0 0 0 0 0 0 0 
1.0 235029 0.0031 0.0031 0.0812 0.0812 0.0259 
1.5 526718 0.0071 0.0102 0.1819 0.1851 0.0589 
2.0 772767 0.0103 0.0205 0.2669 0.2771 0.0883 
2.5 1183818 0.0158 0.0364 0.4089 0.4294 0.1368 
3.0 1579673 0.0211 0.0575 0.5456 0.5820 0.1854 
3.5 2014659 0.0270 0.0845 0.6958 0.7534 0.2399 
4.0 2333564 0.0312 0.1158 0.8060 0.8905 0.2836 
4.5 2787282 0.0373 0.1531 0.9627 1.0785 0.3435 
5.0 3187721 0.0427 0.1957 1.1010 1.2541 0.3994 
5.5 3540175 0.0474 0.2431 1.2228 1.4185 0.4517 
6.0 3907396 0.0523 0.2954 1.3496 1.5927 0.5072 
 
79 
 
 
 
Figure 3.20: In vitro permeation profile for the cumulative amount of O.C penetrated per unit 
area of synthetic membrane (mg/cm²) for gel no. 5 through a synthetic membrane using HPMC 
2% as gelling agent and Cremophor RH40 1% as a penetration enhancer  
 
 
 
Figure 3.21: In vitro steady state flux diagram of orphenadrine citrate (mg/cm²) through a 
synthetic membrane for gel no. 5 through a synthetic membrane using HPMC 2% as gelling 
agent and Cremophor RH40 1% as a penetration enhancer 
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Table 3.26: Diffusion parameters for Gel no. 5 through a synthetic membrane using HPMC 2% 
as gelling agent and Cremophor RH40 1% as a penetration enhancer 
 
Gelling 
Agent 
PE Slope TL D P K 
HPMC 2% Cremophor 1% 0.105 1.2 h 0.0000501 0.0105 3.98 
 
The permeability coefficient of gel no. 5 is divided over the permeability coefficient of gel no. 4 
to determine the enhancement ratio. (See table 3.27) 
 
Table 3.27: The effect of viscosity on drug permeation using cremophore RH40 as penetration 
enhancer and HPMC as gelling agent 
 
Gel 
No. 
Gelling 
Agent 
PE 
Vescosity 
×10³ cps 
Slope TL D P K ER 
4 HPMC 3% Cremophor 1% 30 0.047 1.4 h 0.0000429 0.0047 2.1 1 
5 HPMC 2% Cremophor 1% 7 0.105 1.2 h 0.0000501 0.0105 3.98 2.23 
 
 
As the viscosity decreased the permeation of the API increased. 
 
 
 
 
 
 
 
 
 
 
 
81 
 
3.7. Human Skin Permeation results   
 
The best penetration enhancer (Cremophor RH40) was used with orphenadrine citrate in the gel 
formula and it was tested for permeation through the stratum corneum of  human skin using a 
MFDC. The gel formula used was gel formula no. 4:  
 
Gel formula no. 4: Orphenadrine citrate 1%, Cremophore RH40 1%, HPMC 3%, Glycerin 
5%, Methylparaben 0.1% 
 
The gel specifications are shown in table (3.28), and the data obtained are shown in table (3.29) 
 
Table (3.28): Specifications of final gel formula (no.4) that was tested for permeation through 
human skin. 
 
Specification Description 
Color Colorless 
pH 3.61 
Viscosity 30×10³ cps 
Spreadability Easily spreadable 
Crystals Clear 
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Table 3.29: The Data obtained from the diffusion study through human skin using HPMC 3% as gelling agent and Cremophore 1% as 
penetration enhancer 
hrs Area 1 
Amount1 
mg/ml 
Area 
2 
Amount2 
mg/ml 
Area 
3 
Amoun3 
mg/ml 
Mean 
mg/ml SD RSD 
cumulative 
mg/ml mg/25.8ml 
Q 
[mg] 
m 
[mg/cm2] 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1.0 0.278 0.0011 0.276 0.0011 0.288 0.0012 0.0011 0.000026 2.3 0.0011 0.0290 0.0290 0.0092 
1.5 0.315 0.0013 0.317 0.0013 0.315 0.0013 0.0013 0.000005 0.4 0.0024 0.0326 0.0337 0.0107 
2.0 0.479 0.0019 0.479 0.0019 0.483 0.0019 0.0019 0.000009 0.5 0.0043 0.0496 0.0519 0.0165 
2.5 0.590 0.0024 0.598 0.0024 0.594 0.0024 0.0024 0.000016 0.7 0.0067 0.0613 0.0656 0.0209 
3.0 0.693 0.0028 0.700 0.0028 0.694 0.0028 0.0028 0.000015 0.5 0.0094 0.0718 0.0785 0.0250 
3.5 0.828 0.0033 0.823 0.0033 0.826 0.0033 0.0033 0.000010 0.3 0.0127 0.0852 0.0947 0.0301 
4.0 0.895 0.0036 0.908 0.0036 0.899 0.0036 0.0036 0.000027 0.7 0.0163 0.0929 0.1057 0.0337 
4.5 1.030 0.0041 1.027 0.0041 1.029 0.0041 0.0041 0.000006 0.1 0.0205 0.1062 0.1225 0.0390 
5.0 1.081 0.0043 1.088 0.0044 1.084 0.0043 0.0043 0.000014 0.3 0.0248 0.1119 0.1324 0.0422 
5.5 1.215 0.0049 1.220 0.0049 1.214 0.0049 0.0049 0.000013 0.3 0.0297 0.1255 0.1503 0.0479 
6.0 1.301 0.0052 1.299 0.0052 1.302 0.0052 0.0052 0.000006 0.1 0.0349 0.1342 0.1639 0.0522 
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Figure 3.22: In vitro permeation profile for the cumulative amount of O.C penetrated per unit 
area of Human skin (mg/cm²) for gel no. 4 using HPMC 3% as gelling agent and 
CremophoreRH40 1% as penetration enhancer 
 
 
 
Figure 3.23: In vitro steady state flux diagram of orphenadrine citrate through a human skin for 
gel no. 4, using HPMC 3% as gelling agent and Cremophore RH40 1% as penetration enhancer 
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Table 3.30: Diffusion parameters for gel no. 4 through human skin using HPMC 3% as gelling 
agent and Cremophore RH40 1% as penetration enhancer 
 
Gel 
No. 
Gelling 
Agent 
PE Slope TL D P K 
4 HPMC3% Cremophore1% 0.009 0.22 0.00000170 0.0009 0.794 
 
 
 
The effect of Cremophor RH 40 1% on the permeation of orphenadrine citrate through synthetic 
membrane and human skin is shown in table (3.31) 
 
Table 3.31 Summery of the effect of Cremophor RH40 on the permeation of Orphenadrince 
citrate using MFDC, through synthetic and Human skin for gel no. 4 
 
Gel 
no. 
Gelling 
Agent 
PE 1% 
Membrane 
Type 
Slope TL D P ER 
4 HPMC3% Cremophor Human Skin 0.009 0.22 h 0.00000170 0.0009 1 
4 HPMC 3% Cremophor Synthetic 0.047 1.40 h 0.0000429 0.0047 5.2 
 
The API showed less penetration through human skin than through the synthetic membrane 
because the skin has a more complex structure. In order for the API to penetrate through the skin 
it must penetrate the intercellular lipid matrix which is composed of bi-layer lipid matrix with 
hydrophilic and hydrophobic channels. The lipid bi-layer contains ceramides, fatty acids, 
cholesterol and cholestryl esters. The synthetic membrane on the other hand is composed of 
octanol soaked filter membrane (hydrophobic layer) sandwiched between two dialysis 
membranes (hydrophilic layer).  
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Part Four 
Conclusion  
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Conclusion 
 
In the present work, the solubility of orphenadrine citrate was determined in different solutions 
and was found to increase as the pH increases 
Compatibility study of orphenadrine citrate with different excipients was carried out; almost all 
excipients were found to be compatible with orphenadrine citrate except carpobol, Urea and 
sodium lauryl sulfate 
The influence of selected penetration enhancers included in a 1 % w/w orphenadrine citrate 
aqueous and gel preparation was investigated. The ehancement ratio was calculated for 
each penetration enhancer and found to be in the following order: 
Cremophor RH40 > Urea > -Cyclodextrin > Tween 80 > Propylene glycol 
Topical muscle relaxant, orphenadrine citrate gel was formulated with the selected 
penetration enhancer cremophor RH40. The best gelling agent was found to be HPMC. 
As the viscosity of the O.C gel decreased the drug permeability through the synthetic 
membrane increased and when the concentration of Cremophor RH40 is increasesd to 1% 
in the gel formula the permeability of O.C increased. 
The synthetic membrane showed better permeation results than the skin, suggesting that the 
human skin is more complex than the synthetic bio-membrane 
Some penetration enhancers increased the partition coefficient and others increased the diffusion 
coefficient, combinations of these penetration enhancers are recommended for further 
enhancement of O.C permeability. 
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Part Five 
Appendix 
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Figure 5.1: A chromatograph of O.C reference standard using Dionex HPLC. 
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5674/'84.9:'";4  :cremophor, SLS, Urea, PG, Cyclodextrin, oleic acid, 
Tween 80  
<)	=2>?.'1  %'>1 %?@4.?. <-	A4-3'	B'5 !"	#
56 9:' :	:'CD;
?.?0<'
 5"(:-5'3)	'3E'5;'1F' G3'
=@	B#5'<'8-@ H<I'GJC9:'GJCK-LGJC9:'G/@'J:'3'
"J'MN3'9:';4.OJD;
OPA9:'.  
5.Q)5H3'O43'59:'";4MN3'9:';4.OJ$)':  
PG < Tween 80 < Cyclodextrin  < Urea < Cremophore RH 40. 
RN#5J2GS)	'"Q 4T68-)'HPMC, CMC Na U41 %
V 	.<)	.1 !"	#0.2%- 1 %W(683.@ N3'9:'";4
G4'	FX: <-	AX:-RN##'.  
$E3'GI'$>  HPMC  1 % 'J:'3'1 % Cremophor RH40 	/);4.*
$E3'GI'-9:'5CMC Na 5Y'>'59:';4<)	.<'$) 
9:'OJ.  
=9:-#?.9:';4<)	.GZ1GI'	A!/)	'$;-LOPA @ C
U ;=9:-GJ$) I'OPA9:-'J:'3'"0.0009 ?#/#  
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	-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 234'"5.:#O45 _3'5 !"	#/H94.?.'
/H9	[)8-))2.43 GE'R	100G (234'57.4. 
;'c'd 4_	>?.'56 Z3'3'MN1 !"	:  
(HPMC, CMC Na, PG, MP, Tween 80,Cyclodextrin, Cremophore, SLS, Urea, carbapol, Oleic 
acid, glycerin  )  
	
	=e0P03'&'9 25  40  "	#$Gf'?. 
 !OZ3'3'/']1Carbapol O SLS O8-)
5Urea  
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